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Abstract
Background
Type 2 Diabetes Mellitus (T2DM) is reported to affect one in 11 adults worldwide, with over
80% of T2DM patients residing in low-to-middle-income countries. Health systems play an
integral role in responding to this increasing global prevalence, and are key to ensuring
effective diabetes management. We conducted a systematic review to examine the health
system-level factors influencing T2DM awareness, treatment, adherence, and control.
Methods and findings
A protocol for this study was published on the PROSPERO international prospective register
of systematic reviews (PROSPERO 2016: CRD42016048185). Studies included in this
review reported the effects of health systems factors, interventions, policies, or programmes
on T2DM control, awareness, treatment, and adherence. The following databases were
searched on 22 February 2017: Medline, Embase, Global health, LILACS, Africa-Wide,
IMSEAR, IMEMR, and WPRIM. There were no restrictions on date, language, or study
designs. Two reviewers independently screened studies for eligibility, extracted the data,
and screened for risk of bias. Thereafter, we performed a narrative synthesis. A meta-analy-
sis was not conducted due to methodological heterogeneity across different aspects of
included studies. 93 studies were included for qualitative synthesis; 7 were conducted in
LMICs. Through this review, we found two key health system barriers to effective T2DM
care and management: financial constraints faced by the patient and limited access to
health services and medication. We also found three health system factors that facilitate
effective T2DM care and management: the use of innovative care models, increased
pharmacist involvement in care delivery, and education programmes led by healthcare
professionals.
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Conclusions
This review points to the importance of reducing, or possibly eliminating, out-of-pocket costs
for diabetes medication and self-monitoring supplies. It also points to the potential of adopt-
ing more innovative and integrated models of care, and the value of task-sharing of care
with pharmacists. More studies which identify the effect of health system arrangements on
various outcomes, particularly awareness, are needed.
Introduction
The 2015 International Diabetes Federation’s Diabetes Atlas [1] reported that 415 million peo-
ple worldwide, or one in 11 adults, has diabetes, with most having Type 2 Diabetes Mellitus
(T2DM) [1]. Although the incidence and prevalence of T2DM varies by geographical region,
with over 80% of T2DM patients residing in low-to-middle-income countries, T2DM preva-
lence has increased worldwide since 1980 [2]. Health systems play a crucial role in the response
to this rising burden, preventing premature death and disability and improving quality of life
[2, 3]. Yet, while the management of diabetes has been the subject of many systematic reviews
[4–12], these have focused on particular interventions, models of care, or information technol-
ogy support systems. To our knowledge, no systematic review assembles the evidence apprais-
ing the impact of health systems on management of type 2 diabetes mellitus (T2DM). To
address this gap, we systematically review the literature examining the health system-level fac-
tors influencing T2DM awareness, treatment, adherence, and control, and make recommen-
dations for future research and policy considerations.
Methods
A protocol for this study was published on the PROSPERO international prospective register
of systematic reviews (PROSPERO 2016: CRD42016048185). There are several ways in which
the findings could be arranged but, as we were taking a health systems perspective, we used a
conceptual framework developed by Balabanova and colleagues [13], which has been used to
understand aspects of systems that hinder the effective management of non-communicable
diseases [13, 14]. This framework identifies physical resources (e.g. healthcare facilities, phar-
maceuticals, technologies), human resources (e.g. trained health workers), intellectual
resources (e.g. clinical practice guidelines), and social resources (e.g. social capital, organisa-
tional measures to enhance collaboration) as necessary elements of a health system response to
chronic disease challenges. The framework addresses inputs that underpin health system func-
tioning in three key areas, namely service delivery, healthcare financing, and governance.
These areas are recognised as critical elements of effective health system functioning by the
World Health Organization [15]. In this review, following Gilson and colleagues, we define
governance as: everyday actions and decisions that translate policy intentions into practice,
which are “filtered through relationships, underpinned by values and norms, influenced by
organisational structures and resources, and embedded in historical and socio-political con-
texts” [16] that reinforce or challenge institutional exclusion and power inequalities.
Additionally, this framework takes account of the critical role of context in influencing the
health system. In this manuscript, “context” refers to the socio-demographic, economic, and
cultural setting in which health systems are embedded and operate. This framework is guided
by the understanding that health and healthcare systems are complex adaptive systems that are
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dynamic, evolving, have multiple constituent parts, and are often unpredictable, exhibiting
path dependency and feedback loops [17, 18]. As such, the ability of a health system to produce
good outcomes does not rest on the robustness of disparate constituent “blocks”, but on the
integration and alignment of inputs and system functioning components [19]. This approach
has several advantages. First, it ensures that all of the elements of the health system are consid-
ered explicitly. Second, by taking a health systems approach rather than, for example, a clinical
approach based on detection, treatment and control, it is designed to facilitate identification of
actionable points by health policymakers. Third, it identifies important gaps in the evidence
that will be needed to develop a comprehensive health system response to diabetes, thereby
contributing to prioritisation of research efforts. The corresponding disadvantage is that there
will be some areas where there is little or no research. The conceptual framework is shown in
Fig 1 below.
Inclusion and exclusion criteria
We included studies reporting the effects of macro and meso-level health system factors, inter-
ventions, policies, or programmes on T2DM control, awareness, treatment, and adherence.
Box 1 outlines the definitions used and Box 2 details characteristics of included studies.
Fig 1. Conceptual framework.
https://doi.org/10.1371/journal.pone.0195086.g001
Box 1. Definitions of included T2DM outcomes
T2DM awareness: persons with clinically measured T2DM who have been diagnosed by
a healthcare professional and are aware of their T2DM status
T2DM treatment: the use of at least one anti-diabetic medication in an individual with
known T2DM
Anti-diabetic medication adherence: consistently taking antidiabetic medication as per
regiment prescribed by a healthcare provider/professional
T2DM control: defined as the achievement of glycaemic control, blood pressure, and/or
lipid control targets in individuals being managed for T2DM
The influence of health systems on Type 2 Diabetes outcomes
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Quantitative studies were included if they reported a measure of1 association between a
health system element and at least one T2DM outcome. No date or language restrictions were
applied. Translators were engaged to assist in determining the eligibility of non-English lan-
guage literature. Translators helped with translation of titles, abstracts, and studies’ key find-
ings. Studies evaluating interventions or programmes enacted at the micro-level (e.g.
individual- or patient-level), such as those on the genetic profile of T2DM patients, were not
included.
Search strategy
The search strategy drew on that used by Maimaris and colleagues [20] in their health systems
and hypertension systematic review. Key words (MeSH terms) and free-text terms were identi-
fied for each domain of our health systems framework and combined with search terms for
T2DM outcomes to generate search strategies for Medline, Embase, and Global Health. In
addition, modified searches were performed on Latin American and Carribean Health Siences
Literature (LILACS), Africa-Wide, Index Medicus for the South-east Asian Region (IMSEAR),
Index Medicus for the Eastern Mediterranean Region (IMEMR), and Western Pacific Rim
Region Index Medicus (WPRIM). All databases were searched from inception to 22 February
2017.
Study selection
Two reviewers independently screened search results by title and abstract for potential eligibil-
ity. Full-texts of potentially suitable articles were obtained and further screened by two review-
ers. Disagreements were resolved by a third reviewer.
Data extraction for study setting, methodology, and findings
A data extraction form was created in Microsoft Excel. Two reviewers independently extracted
data on design, setting/context, health system domain/s investigated, outcomes and relevant
findings, and checked for disparities.
Risk of bias assessment
Two reviewers independently assessed included studies for risk of bias as low, medium, or
high. For observational study designs (e.g. cross-sectional, case-control, cohort, pre-post,
Box 2. Characteristics of included studies
We included studies looking at any adult population, including general populations,
populations receiving treatment, and populations of T2DM patients with related comor-
bidities, including hypertension and hyperlipidaemia. Included studies fell into two
categories:
Studies undertaken at the macro-level of the health system: this includes, but is not con-
fined to, national and international health policies, national healthcare financing struc-
tures, and national healthcare and health services delivery structures.
Studies undertaken at the meso-level of the health system: this includes, but is not
restricted to, regional-level health systems/authorities, healthcare institutions (e.g. ter-
tiary hospitals), and care organisations/networks (e.g. networks of primary care clinics)
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record/chart reviews) three domains were examined, as per Maimaris and colleagues in their
systematic review [20]: selection bias, information bias (differential and non-differential mis-
classification), and confounding. Assessment of non-differential misclassification considered
the reliability of the measure used to report T2DM outcomes. Studies assessed as having “low”
or “high” risk of bias in most domains were classified as having low or high overall risk of bias
respectively. Those where risk of bias was unclear in two domains, were classified as medium
overall risk and those assessed to have unclear risk in three domains were classified as high
overall risk.
The Cochrane risk of bias tool was used to assess randomised controlled trials, cluster ran-
domised trials, and non-RCT, non-observational studies (e.g. trials that are not randomised or
do not have a control group). Studies assessed as having low risk of bias across most domains
were classified as low overall risk of bias. If risk was unclear in two to three domains and most
domains were not classified as “high” or “low” risk of bias, the study was classified as medium
overall risk of bias. Studies assessed to have unclear risk of bias in four domains were classified
as having high overall risk of bias.
For quality assessment of qualitative studies, we used an adapted version of a checklist pre-
viously used in a series of mixed-methods systematic reviews [21, 22], comprising ten core cri-
teria. Studies with a score of eight to ten were classified as having an overall low risk of bias,
four to seven as overall medium risk of bias, and zero to three as overall high risk of bias.
Assessment of context and complexity considerations
We assessed the extent to which included studies consider context and complexity, in respect
of sociodemographic, political, economic, and/or cultural issues, as well as dynamic relation-
ships between different health systems domains. We also explored how health systems inter-
acted with contextual factors.
Data analysis and synthesis
A narrative synthesis was performed. We categorised studies by health system domain and
study setting, recognising that some investigated multiple domains simultaneously. Rando-
mised controlled trials (RCTs) were considered the strongest design to establish causality, fol-
lowed by cohort and case-control studies. Cross-sectional and ecological studies were not
considered adequate to establish causality. We did not conduct a meta-analysis due to hetero-
geneity across study designs, populations, comparisons, analytical strategies, and outcomes
[20].
Results
We describe the screening process using an adapted Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) flowchart [23], shown in Fig 2 below.
Database searching identified 6,975 records, with 5,620 remaining after duplicate removal.
After screening of titles and abstracts, 175 full-text articles were retrieved. 93 were included in
the final qualitative synthesis. Of these 84 were quantitative. Of these, 21 were randomised
controlled trials; one was a cluster randomised controlled trial; three were cluster randomised
pragmatic trials; three were trials (i.e. trial designs with no mention of randomisation); 15
were cohort studies; one was a case-control study; 19 were cross-sectional studies; 14 were pre-
post studies; six were record/chart reviews; and one was a time-series analysis. Of the remain-
ing nine studies, six were qualitative and three used mixed methods. 77 (83%) of included
studies were carried out in World Bank-classified high-income countries, nine in upper-mid-
dle income countries, and seven in lower-middle income countries.
The influence of health systems on Type 2 Diabetes outcomes
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Geographical distribution of included studies
As shown in Fig 3, most studies took place in North America (n = 53) and Europe (n = 16),
with fewer in Asia (n = 10), Africa (n = 6), South America (n = 1), the Middle East (n = 3), and
Australia (n = 4). Notably, all studies of healthcare financing were conducted in North Amer-
ica (n = 14).
Risk of bias assessment
We conducted risk of bias assessment for all 93 articles. 28 studies had their risk of bias
assessed using the Cochrane risk of bias tool. Of these, 22 were randomised controlled trials.
12 had high risk of bias [24–35], eight had medium risk of bias [36–43] and one had low risk
of bias [44]. One cluster randomised controlled trial was assessed to have low risk of bias [45].
Three were cluster randomised pragmatic trials; two had high risk of bias [46, 47] and one had
low risk of bias [48]. Three studies were trials: two had high risk of bias [49, 50] and one had
medium risk of bias [51].
Among the 56 studies assessed as observational study designs, 19 were cross-sectional, of
which seven had high risk of bias [52–58], four had a moderate risk of bias [59–62] and eight
had low risk of bias [63–70]. 15 were cohort studies; one study had a high risk of bias [71], five
had a medium risk of bias [72–77], and eight had low risk of bias [78–85]. One study used a
case-control study design and had a moderate risk of bias [86]. 14 were pre-post studies; one
had a high risk of bias [87], 11 had medium risk of bias [88–98], and two had low risk of bias
Fig 3. Geographical distribution of included studies.
https://doi.org/10.1371/journal.pone.0195086.g003
Fig 2. Adapted PRISMA flowchart.
https://doi.org/10.1371/journal.pone.0195086.g002
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[99, 100]. Six studies were record/chart reviews: two were assessed to have low risk of bias
[101, 102] and four had medium risk of bias [103–106]. The one time-series study in this
review had a medium risk of bias [107].
Six qualitative studies were assessed for risk of bias using a tool adapted from the Consoli-
dated Criteria for Reporting Qualitative Studies (COREQ) checklist. One had a moderate risk
of bias [108], and five had low risk of bias [109–113].
Risk of bias in the three mixed-methods studies was assessed separately for the quantitative
and qualitative components. All three studies had quantitative components with a high risk of
bias. One study had a moderate risk of bias for the qualitative component [114] and two had a
low risk of bias for the qualitative component [115, 116].
Context
32 of 93 included studies gave no detailed information about the socio-demographic, political,
or economic context in which the study was conducted [26, 28–30, 34, 36, 37, 39, 40, 44, 45,
47, 52, 53, 55, 57, 64, 65, 68, 70, 72, 73, 84, 87, 89, 90, 95, 97, 101, 103, 105, 110]. 61 included
studies that provided contextual information on various levels.
Three studies described the regional context, such as Sub-Saharan Africa and South Amer-
ica [49, 83, 99]. Such studies tended to consider context within the narrative of diabetes control
in their region. 32 studies described the national context in which the study took place [25, 27,
31, 33, 42, 43, 48, 50, 51, 54, 59–62, 66, 67, 74, 80–82, 85, 86, 91, 92, 96, 98, 100, 104, 111, 112,
115, 116]. This typically involved descriptive statistics to indicate the magnitude and urgency
of diabetes as a national challenge, highlighting incidence or prevalence rates and cost burden.
These descriptions ranged from brief summaries to comprehensive elaborations. 16 studies
described the health system context in which the study took place [32, 35, 46, 58, 69, 75, 78, 88,
93, 94, 102, 106–110]. The contexts described ranged from broad and general to in-depth and
extensive.
10 studies considered the context of the population studied or the specific intervention.
Examples included the role of healthcare professionals involved in the intervention [38, 77],
descriptions of demographic context (e.g. low-income, indigenous, Hispanic) in which an
intervention took place [24, 41, 71, 76, 79, 113, 114], and existing structures in which interven-
tions occurred (e.g. financing of prescription medications in the Veterans Affairs healthcare
system) [56]. Table 1 provides examples of context considerations in included studies.
Effect of health system inputs on diabetes outcomes
37 studies explored the impact of health system inputs on diabetes outcomes. The analysis
explores studies that had a focus on one type of resource, and complex interventions involving
studies with more than one type of resource or system building block. Table 2 summarises the
findings of included studies exploring the associations between health systems inputs and dia-
betes outcomes.
Physical resources. One cross-sectional study from the United States found an associa-
tion between driving distance from primary care facility and likelihood of insulin use (odds
ratio (OR) for using insulin associated with each kilometre of driving distance, 0.97, 95%
confidence interval (CI) 0.95, 0.99; p = 0.01) [68]. Living within 10km of a primary care
facility was associated with increased likelihood of insulin use (OR 2.29, 95%CI 1.35–3.88;
p = 0.02).
Human resources. 36 studies examined the effect of human resource inputs on diabetes
outcomes.
The influence of health systems on Type 2 Diabetes outcomes
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Pharmacists: 17 quantitative studies explored the impact of pharmacists on diabetes out-
comes. All but one [88] took place in high-income countries. 11 found positive effects of phar-
macist care on diabetes control and adherence outcomes.
Seven studies from high-income countries reported positive impacts of pharmacists admin-
istering patient care. Two trials, both conducted in the United States, obtained positive results.
One found a significantly greater absolute percent decrease in HbA1c from baseline among
those seeing a pharmacist [30]. The other, in university owned neighbourhood clinics,
Table 1. Examples of context considerations in included studies.
Scale Description Example(s)
Regional Extensive “There is substantial evidence to support the fact that diabetes is
assuming epidemic proportion in many developing countries,
including those of Sub-Saharan Africa (SSA). Of the 246 million
estimated global population with diabetes in 2007, 10.7 million
resided in Sub-Saharan Africa. This number will increase by 80%
to reach 18.7 million by the year 2025. Type 2 diabetes in
developing countries and those of Africa is characterized by a
high proportion of undiagnosed patients, reaching 80% in some
settings. The insidious nature of type 2 diabetes and the low
availability and less accessibility of the African population to
healthcare contribute to this situation. The consequences of late
diagnosis are that most patients in Africa tend to present with
chronic complications at diagnosis.”[99]
National Extensive “Diabetes is emerging as a major clinical and public health
concern among the Kuwaiti population. The reported prevalence
rate of known type 2 diabetes in 1990 was 7.6%, ranging from
5.6% to 10% in different governorates. In 1996, the overall
prevalence rate of type 2 diabetes in Kuwaiti adults of age 20
years and over was as high as 14.8%. A remarkable increase in
prevalence has been reported in more recent studies. In one
study utilizing a cross-sectional household survey of 2,487
Kuwaiti nationals aged 50 years and over in 2005/2006 from two
health governorates, the prevalence of physician-diagnosed
diabetes was found to be 50.6%. Type 2 diabetes was detected
even in adolescents, according to a population study of Kuwaiti
school children, making the disease a public health problem. The
burden of diabetes in Kuwait is high, and it has a serious impact
on morbidity and mortality.”[112]
Brief “Like in many other countries, chronic care tasks are
increasingly being delegated from general practitioners (GPs) to
nurses in Danish general practices”[67]
“in the United States alone the total financial cost attributable to
diabetes was estimated at $132 billion”[31]
Health System Brief “[Christiana Care Health System] CCHS is the largest health care
provider and the largest private employer in Delaware. CCHS is
self-insured and, like most large companies, has experienced
rapid growth in health care expenditures over the past decade.”
[74]
Extensive “The Medicare Part D program, introduced on January 1, 2006,
provides prescription drug coverage for Medicare beneficiaries.
One unique feature of the Part D benefit design is the coverage
gap (or donut hole). The defined standard benefit in 2008 started
with a $275 deductible and a 25% copayment for drug spending
between $275 and $2510. After the initial coverage period,
beneficiaries entered a coverage gap, in which they paid 100% of
the drug cost, until their true out-of-pocket drug spending
reached the catastrophic limit of $4050 (or total drug spending of
$5726.25). Under the catastrophic coverage, beneficiaries pay the
greater of a 5% or a $2.25/$5.60 (generic/brand-name)
copayment.” [75]
(Continued)
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reported that the intervention group achieved reductions in HbA1c with fewer physician visits
compared to patients receiving usual care [33].
A cohort study in the United States reported a lower mean HbA1c among those in an out-
patient programme involving face-to-face pharmacist consults (p = 0.024), and significantly
reduced from baseline [76]. Although there was no significant between-group difference in
mean medication possession ratio (MPR), intervention patients saw an increase in MPR from
baseline (p = 0.024). Patients receiving the intervention were less likely to discontinue diabetes
medications (p<0.001) and more likely to have their medication prescription 30 days after the
end of their supply of the last prescription following their first consultation date (p< 0.001).
An Australian randomised controlled trial found that a pharmacist-delivered community-
based care and management programme was associated with a mean decrease in blood glucose
levels over six months [32]. Improvements in HbA1c were greater in the intervention group
(-0.97% (95% CI: -0.8, -1.14, p<0.01) compared to controls (-0.27% (95% CI: -0.15, -0.39,
p<0.01)).
A pre-post study from the United States found that an intervention with pharmacists
adjusting medications, evaluating therapeutic needs, and developing care plans recorded sig-
nificantly lower mean HbA1c readings compared with the control group after one and two
years. The two-year average decrease in HbA1c was greater for the intervention group com-
pared to the control (p = 0.009) [100].
Table 1. (Continued)
Scale Description Example(s)
Context of direct
population studied
Role of healthcare
professionals
“Like many health systems nationally, the Veterans Health
Administration (VA) is undergoing a major transformation of
primary care to team-based care, by implementing a patient
centered medical home (PCMH) model system wide to improve
access, coordination, and continuity of care. Pharmacists have
been recommended as a standard component of patient-
centered medical homes, but their impact on OHA adherence
has not been studied. Pharmacists in VA primary care clinics
may have a clinically oriented role by providing counseling and
education to patients taking diabetes medications. However,
pharmacists in VA may also be limited to a purely dispensing
role or simultaneously manage both clinical and dispensing
tasks.”[77]
Demographic “Indigenous Australians have the highest prevalence and
incidence of diabetes in Australia and also suffer high rates of
preventable complications. Many of these complications can be
prevented with better primary care level management however
access to culturally appropriate high quality diabetes care is not
always evident, especially in remote settings where there is high
turnover of health staff. Australian Indigenous adults with type 2
diabetes are on average 10 years younger, have poor glycemic
control and lower levels of preventive service up-take compared
to non-Indigenous adults with diabetes in a national sample”[41]
Financing structures “Veterans Health Administration (VA) medical centers offer
more comprehensive medication coverage than almost any other
public or private payer in the United States. Drugs on the VA
formulary are 100% covered for patients with low incomes or
service-connected disabilities. Other VA patients pay a $7
copayment for a 30-day supply of medication treating a
nonservice-connected condition. VA patients have no cap on
either the total cost of their covered drugs or the number of
prescriptions they can fill in a given period, and patients who
incur $840 or more in copayment costs during a given year have
all subsequent copayments waived.”[56]
https://doi.org/10.1371/journal.pone.0195086.t001
The influence of health systems on Type 2 Diabetes outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0195086 March 29, 2018 9 / 42
Table 2. Summary of findings of studies examining the associations between health systems inputs and T2DM outcomes.
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Physical Resources
Distance to health facility Littenberg.
2006
USA–Patients managed in
Primary Care
N = 781
Cross-sectional • OR 0.97 (0.95–0.99) for insulin use
per km of driving distance
Low risk of
bias
Human Resources
Pharmacists
Follow up intervention with pharmacist Bello et al.
2012
Nigeria–Patients in a primary
health facility
N = 170
Pre-post • Mean A1C reduced from 8.08 pre-
intervention to 7.08 post-intervention
(p<0.001)
Medium risk
of bias
Pharmacist-patient clinic visits
including medication review,
performing targeted physical
assessment, education, reviewing patient
medication therapy
Jacobs et al.
2012
USA- Patients in primary care
N = 2121
Randomised
controlled trial
• Greater absolute % change in A1c
from baseline for intervention group
than control group who received usual
care directed by their physicians (-0.18
vs -0.8%) (p<0.05)
High risk of
bias.
Pharmaceutical care initiative (Medical
record review, pharmacotherapeutic
evaluation and patient medication
education and monitoring
Taylor et al.
2003
USA-Patients from areas of
severe poverty, low insurance
coverage and poor health
indicators going to
community based family
clinics
N = 69
Randomised
controlled trial
• At 12 months, intervention-group
patients more likely than control
patients to achieve blood pressure (BP)
targets (intervention 91.7% vs. control
27.6%, p = 0.001)
• At 12 months, increase from baseline
in the percentage of patients at BP
(12.5% vs 91.7%, p<0.001), lipid
(10.5% vs 77.8%, p<0.001) goals in
intervention group
• Control group received standard
medical care.
High risk of
bias
Outpatient clinical pharmacist
programme (face to face consult with
patients, decision support tool for
medication prescription)
Spence et al.
2014
USA- Kaiser permanente
health system
N = 2957
Cohort • Mean HbA1c in intervention group
lower than usual care group (8.48 vs.
8.80, P = 0.024)
• Reduction in HbA1c from baseline
(-1.25 vs. -0.75, P = 0.001)
• 53.5% of intervention group
adherent to diabetes medications after
1 year, compared with 37.4% in the
usual care group (P = 0.001)
• Intervention group saw increase in
medication possession ratio (MPR)
from baseline compared with usual
care group (0.19 vs. 0.15, P = 0.024
• Intervention patients less likely to
discontinue diabetes medications
(11.7% vs. 35.5%, P < 0.001) and more
likely to have their medication
prescription filled within 30 days after
the end of their supply of the last
prescription post-first consultation
date (34.8% vs. 12.9%, P< 0.001)
• Average days to first medication
prescription filled after first
consultation date was 79.3 for the
intervention group compared with
156.3 for the usual care group (P<
0.001)
Medium risk
of bias
Pharmacist-delivered, community
pharmacy-based diabetes care and
management programme, including
support for blood glucose self-
monitoring, education, adherence
support, and reminders of checks for
complications
Krass et al.
2007
Australia- patients collecting
medication in community
pharmacies
N = 289
Randomised
controlled trial
• Mean reduction in HbA1c in the
intervention group was -0.97% (-0.8,
-1.14) compared with -0.27% (-0.15,-
0.39) in the control group who
received usual care from pharmacists
(p<0.01)
High risk of
bias
(Continued)
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Table 2. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Pharmacist allowed to adjust medication
and met with patient to evaluate patient
therapy needs and to develop a patient
care plan
Ko et al. 2016 USA–patients in an integrated
health maintenance
organization
N = 150
Pre-post • Intervention group had lower mean
A1c readings compared with control
after 1 year (8.18% vs 8.69%, p = 0.012)
and 2 years (8.06% vs 8.67%,
p = 0.014)
• 2-year average decrease in A1c was
larger in intervention group compared
with usual care group (-1.24 vs -0.59,
p = 0.009)
Low risk of
bias
Pharmacist directly involved in patient
care and management of patient
requiring insulin therapy
Coast-Senior
et al. 1998
USA- patients on insulin
therapy in primary care
clinics
N = 23
Pre-post • Decreased mean HbA1c
concentrations from 11.1% to 8.9%
(p = 0.00004)
Medium risk
of bias
Pharmacist intervention (education
session and information leaflet
distribution)
Vella et al.
2013
Malta- Pharmacies in Malta
N = 30
Pre-post • Improvement from 24 patients
reporting rarely missing a dose of
medication pre-intervention to 8
patients post-intervention
• Pre-intervention 1 patient reported
to "never miss a dose" of medication";
increased to 22 post-intervention
Medium risk
of bias
Pharmacist led shared medical
appointments program which included
an educational component
Cohen et al.
2011
USA- patients in a veteran’s
affairs medical centre
N = 99
Randomised
controlled trial
• Compared to standard primary care,
treatment group had significant
reductions in A1C (-0.41; 95% CI-0.74
to -0.07%, p<0.05).
• Compared to standard primary care,
treatment group had higher adjusted
odds of achieving A1C goals (aOR,
2.73; 95% CI 1.03 to 7.16, p<0.05) and
SBP goals (adjusted odds ratio, 3.06;
95% CI, 1.31 to 7.16, p<0.05)
High risk of
bias
Pharmacist-led, patient-centred
pharmacotherapy management program
(interdisciplinary approach to patients
with complex disease state and
medication burdens, consultation with a
pharmacist where patients were
instruced on blood glucose monitoring
an dietary practices)
Monte et al.
2009
USA- Patients in regional
primary care group
N = 50
Pre-post • At 6 months and 12 months, A1C
and fasting plasma glucose (FPG)
reduced compared to baseline (6
months: A1C, -1.1%, p<0.0001 and
FPG, -39 mg/dL, p = 0.003. 12 months:
A1C -1.1%, p<0.0001and FPG -35 mg/
dL, p = 0.005)
Medium risk
of bias
Integration of pharmacist practice into
patient-centred medical home
Berdine et al.
2012
USA- Patients in a medical
home
N = 200
Pre-post • Mean A1C decreased from baseline
at 1 year (8.3% to 7.7%, p<0.0001) and
2 years (8.25% to 8.10%, p = 0.006)
Medium risk
of bias
Addition of pharmacist to primary care
team
Simpson et al.,
2011
Canada- Primary care clinics
in a primary care network
N = 260
Randomised
controlled trial
• Over 1 year, reduction in SBP for
intervention patients (-7.4mmHg, 95%
CI 4.6–10.2, p<0.001) but no
significant reduction in control
patients who received usual care by
primary care team
• Between-group difference in SBP at 1
year in favour of intervention
(4.9mmHg, 95%CI 1.0–8.7, p = 0.01)
• OR 2.55 (95%CI 1.3–5.01,
p = 0.0065) for 10% decrease in SBP
Medium risk
of bias
(Continued)
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Table 2. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Face to face meeting with community
pharmacists every 3 months which
consisted of diabetes counselling
Oyetayo et al.
2011
USA–Hispanic patients
seeking care in a pharmacy
network
N = 126
Cohort • Reductions in FPG (163 vs. 149 mg/
dL, p = 0.019), SBP (87 vs. 85 mmHg,
p = 0.003), and triglycerides (191 vs.
176 mmHg, p = 0.003)
• Subgroup analyses of patients with
poorly controlled diabetes at baseline
revealed reductions in mean HbA1c
(9.2% vs 8.6%, p = 0.006), SBP (147 vs.
143 mmHg, p = 0.031), DBP (91 vs. 87
mmHg, p<0.001), triglycerides (259
vs. 219 mg/dL, p<0.001), LDL-C (139
vs. 123 mmHg, p<0.001), and total
cholesterol (237 vs. 222 mmHg,
p = 0.008)
High risk of
bias
Pharmacists trained in motivational
interviewing on patient-centred
approaches to achieving health goals,
working with patients on intervention
teams in person or over the phone
Heisler et al.
2012
USA- patients in outpatient
primary care clinics
N = 4622
Cluster
randomised
pragmatic trial
• Mean SBPs of intervention group
decreased to a larger extent as
compared to the control group, who
received usual care, after intervention
(difference of -2.4mmHg, 95%CI
-3.4–-1.5, p<0.001)
High risk of
bias
Patients seen by clinical pharmacy
specialists for diabetes management
Quinones
et al. 2016
USA- patients using clinical
pharmacist services in large
urban healthcare system
N = 915
Record/
chart review
• Average HbA1c difference of -2.6%
from initial to final visit (2010–2013,
all p<0.01)
• Increase in patients with DM
achieving HbA1c >7% 2.1% in 2010,
2.7% in 2011 and 2012, and 3.1% in
2014 (all p<0.01)
• Overall increases in absolute
proportion of medication adherence at
time of discharge: 42.8% in 2010,
43.5% in 2011, 42.8% in 2012, 49% in
2013
Low risk of
bias
Pharmacist meetings to initate diabetes
care plan, alongside visits and telephone
calls to facilitate diabetes management
Odegard et al.
2005
USA- patients managed in
Primary care
N = 77
Randomised
controlled trial
• Mean HbA1c in both intervention
and usual care groups decreased from
baseline 6 and 12 months (p = 0.001),
but intervention groups achieved
HbA1c decreases with fewer physician
visits
High risk of
bias
Presence of pharmacists in clinics Kocarnik et al.
2012
USA–Patients managed in
Veteran’s Affairs health
system
N = 280603
Cohort • No statistically significant effect of
pharmacist presence on patients’
medication adherence
Medium risk
of bias
Nurses
Empowering nurses with no previous
experience in management of chronic
diseases to be directly in charge of
running the clinics
Kengne et al.
2009
Cameroon- T2DM patients
N = 225
Pre-post • 1.6mmol/L difference in mean FPG
levels between baseline and final visit
(95% CI: 0.8–2.3, p<0.001)
Low risk of
bias
Transferring diabetes care to nurses
specialized in diabetes in secondary care
Houweling
et al. 2009
Netherlands- Patients
managed in general practice
N = 93
Randomised
controlled trial
• After 1 year, more intervention
group patients (2.2% to 33.3%,
p<0.002) achieved target HbA1c <7%
compared to control group who
received standard care (10. 5% to
26.3%)
•
High risk of
bias
(Continued)
The influence of health systems on Type 2 Diabetes outcomes
PLOS ONE | https://doi.org/10.1371/journal.pone.0195086 March 29, 2018 12 / 42
Table 2. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Involvement of nurses in diabetes care
in general practice
Juul et al. 2012 Denmark–Patients in general
practice
N = 258
Cross-sectional • Proportion of patients with HbA1c
8 was -3.7% (95%CI -6.7 to -0.6%)
between practices with well-
implemented nurse-led diabetes
consultations compared with no
nurses employed (p<0.05)
Low risk of
bias
Nurse practitioners in collaborative
practices with primary care clinicians in
helping improve control of HbA1c, BP,
and LDL-C in adults with uncontrolled
hyperglycemia
Richardson
et al. 2014
USA- Patients in 2
ambulatory care internal
medicine modules in the
Kaiser permanente health
system
N = 28
Record/
chart review
• Post-intervention, 13 patients (50%)
achieved HbA1c <8% compared to
pre-intervention (0 patients)
(p<0.001)
Medium risk
of bias
Transferring diabetes management to
practice nurses in primary care setting
Houweling
et al 2011
Netherlands- patients
managed in general practice
Randomised
controlled trial
• No significant between-group
differences with respect to reduction
in HbA1c, blood pressure and lipid
profile
• Control group received conventional
care from general practitioners
High risk of
bias
Involvement of non-ICU nurses,
providing specific training an obligatory
certifation, and independent authority
of all certified nurses to initate the
correctional insulin algorithm in
patients with diabetes
Manders et al.
2016
Netherlands- patient admitted
to a medical centre
N = 410
Trial • No significant differences in mean
blood glucose and FPG levels between
intervention and control groups
• Control group was derived from
patients hospitalised prior to
implementation of the intervention.
High risk of
bias
Nurse behavioural management of
diabetes and hypertension in
community practices
Edelman et al.
2015
USA- patients in primary care
N = 377
Randomised
controlled trial
• No A1c and SBP differences between
intervention group compared to
control group, who received calls
which were not tailored and discussed
topics not relevant to diabetes or
hypertension management.
•
Medium risk
of bias
Clinic nurse practitioners had visits to a
diabetes specialist, conference calls,
guidance by faxing flow sheets to
specialist and 24 hour reponse to
critique treatment plan
King et al.
2009
USA- Patients in primary care
N = 135
Randomised
controlled trial
• No significant reduction in HbA1c
from baseline comparing treatment vs.
control group
• The control group was not contacted,
and only their charts were reviewed by
the research team.
High risk of
bias
Community health workers
Community health workers delivery
diabetes curriculum targeting barriers to
diabetes management
Collinsworth
et al. 2013
USA–diabetes self-
management program for
uninsured and underserved
patients
N = 497
Mixed methods • Improved mean A1C value from
8.7% at to 7.4% following participation
(p<0.001)
• Improved mean SBP (baseline
129.8mmHg vs. 1-year follow-up
127.3, p = 0.03)
High risk of
bias
Recruited an indigenous health worker
resident in the community to work as
part of the primary care team, they were
trained on clinical aspects of diabetes
and other chronic conditions, and how
to manage diabetes.
McDermott
et al. 2015
Australia- poorly controlled
patients with diabetes in
indigenous communities
managed in primary care
N = 213
Randomised
controlled trial
• At 18 months follow-up, HbA1c
reduction in the intervention group
(10.8% to 9.8%) was greater than
reduction in control group (10.6% to
10.3%), p = 0.0018
• The control group was placed on an
intervention waitlist, and given the
intervention after the study.
Medium risk
of bias
(Continued)
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Table 2. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Community health workers compared to
case management and usual care
Babamoto
et al. 2009
USA–Hispanic patients
managed in family health
centres
N = 318
Randomised
controlled trial
• Mean A1C decreased from 8.6% to
7.2% (p<0.05) in the community
health worker group, 8.5% to 7.4%
(p<0.05) in the case management
group, 9.5% to 7.4% (p<0.05) in the
standard provider care group
• Proportion of patients who reported
never forgetting to take their
medication decreased in case
management (77%to 55%, p <0.05)
and standard provider care groups
(67% to 50%, p < 0.05)
• Proportion of patients reporting
never forgetting to take their
medication decreased in case
management (77%to 55%, p <0.05)
and standard provider care groups
(67% to 50%, p <0.05)
High risk of
bias
Peers
Reciprocal peer support programme
conducted (i.e. an intervention at
encouraged patients receive and provide
support to one another)
Heisler et al.
2010
USA- Veterans managed in
nurse care management
N = 244
Randomised
controlled trial
• Mean HbA1c levels in intervention
group reduced (-0.29%); mean HbA1c
levels control (nurse case
management) group increased (0.29%)
(between-group difference 0.58%,
p = 0.004)
• Among patients with baseline HbA1c
>8.0%, intervention group had a mean
decrease of 0.88%, compared with a
0.07% decrease in control group
(between-group difference 0.81%,
p<0.001)
Low risk of
bias
2-year peer support intervention
(included recruitment and training of
peer supporters, nine group meetings
led by peer supporters in participant’s
own general practice, and a retention
plan for peer supporters)
Smith et al.
2011
Ireland- Patients in general
practice
N = 395
Cluster
randomised
controlled trial
• At two-year follow-up, no significant
differences in HbA1c, SBP, total
cholesterol despite trend towards
decreases in proportion of patients
with poorly controlled risk factors at
follow-up
Low risk of
bias
Physicians
Regular physician for diabetes care Hueston et al.
2010
USA- patients at a family
medicine centre of a
university hospital
N = 705
Record/
chart review
• Patients with a regular provider had
lower average HbA1C (7.7 vs. 8.5,
P = 0.01) compared to patients without
Medium risk
of bias
GP screening activity Spigt et al.
2009
Netherlands- Primary care
centres in a university
network
N = 58919
Record/
chart review
• Patients with diabetes in primary
care had worse HbA1c than patients in
secondary/tertiary care (pri care
8.4 ± 1.8% vs. sec/ter care 8.1 ± 1.6%,
p < 0.001)
• Patients with diabetes treated in
primary care setting had better BP
control than those in secondary/
tertiary setting (BP target 140/90
mmHg, pri care 42.3% vs. sec/ter
46.6%, p < 0.05)
Low risk of
bias
(Continued)
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Another pre-post study from the United States found that involving clinical pharmacists in
direct patient care of insulin-dependent patients in primary care led to a significant decrease
in mean HbA1c post-intervention [94]. A Maltese pre-post study found that an education-
focused pharmacist intervention was associated with a smaller proportion of patients “rarely”
missing a dose of medication and a larger proportion of patients reporting “never missing a
dose” of medication post-intervention [98].
Four studies reported positive impacts of pharmacist-led patient management. A rando-
mised controlled trial in the United States found that pharmacist-led shared medical appoint-
ments was associated with significant reductions in HbA1C (-0.41; 95% CI -0.74 to 0.07) and
significantly higher odds of attaining HbA1C goals (adjusted OR 2.73; 95% CI, 1.03 to 7.16)
compared to usual care [26]. A pre-post study in the United States found that a pharmacist-
led, patient-centred pharmacotherapy management programme was associated with signifi-
cantly reduced HbA1c and fasting plasma glucose parameters for patients with diabetes who
had complex disease and medication burdens at six and 12 months when compared to baseline
[91]. A Nigerian pre-post study found reductions in mean HbA1c and fasting blood sugar in
those receiving monthly follow up pharmacists over three months at a primary healthcare
facility [88]. A pre-post study in the United States found that having a pharmacist practice in a
patient-centred medical home (a team-based model of care led by a personal physician who
provides continuous and coordinated care throughout a patient’s lifetime to 15 outcomes) was
associated with significant decreases in patients’ mean HbA1c from baseline at one- and two-
year time points [89].
Table 2. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Clinical inertia (inadequate
intensification of therapy by the
provider)
Ziemer et al.
2005
USA- Diabetes clinic
N = 2157
Cohort • Tendency of individual providers to
intensify therapy associated with lower
HbA1C levels (P < 0.0001)
• 10% higher frequency of
intensification associated with a 0.15%
lower level of A1C
• A single episode of intensification of
therapy associated with an average
0.7% A1C reduction
Low risk of
bias
Physician certification Pinsky et al.
2011
USA- Nationwide data
N = 8011
Record/
chart review
• Patients managed by certified
physicians (certification recognises
physicians and practices providing
high-quality diabetes care) more likely
to receive prescriptions for oral
antihyperglycemic agents than those
managed by non-certified physicians
(mean prescriptions per patient per
month 0.49 vs. 0.46, p = 0.02)
Medium risk
of bias
Vocational registration of GPs Kamien. 1994 Australia–audit data of GP
practitioners and patients
N = 671
Cross-Sectional • No difference in HbA1c between
vocationally registered and non-
vocationally registered doctors
Medium risk
of bias
Patient- physician gender concordance Schmittdiel
et al. 2009
USA- Kaiser Permanente
North California
N = 157458
Cross-Sectional • Female patients of female physicians
most likely to have HbA1c<8% (70%
vs. 66%–68%)
• Patient and physician gender
interaction associated with significant
LDL-C control, with male patients of
male physicians having the highest
proportion of patients at or below
target
Low risk of
bias
https://doi.org/10.1371/journal.pone.0195086.t002
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Four studies, all from North America, found mixed effects of pharmacist involvement in
service delivery on diabetes control and adherence outcomes. A Canadian randomised con-
trolled trial [42] found a reduction in systolic blood pressure (SBP) of 7.4mmHg (95%CI 4.6–
10.2; p<0.001) over one year in patients managed by a team to which a pharmacist had been
added, with a between-group difference in SBP of 4.9mmHg, 95%CI 1.0–8.7; p = 0.01. How-
ever, there were no significant changes in glycaemic control and lipid parameters. A pragmatic
cluster randomised trial in the United States found that a clinical pharmacist-led outreach pro-
gramme (working with patients in person or over the phone, motivational interviewing) had
only short-term positive effects for primary care patients [46]. Immediately post-intervention,
the mean SBP of the pharmacist-led group decreased compared to the control group
(-2.4mmHg, 95%CI 1.5–3.4, p<0.001). However, the control group achieved similar results six
months post-intervention. A United States cohort study found that a face-to-face community
pharmacist intervention focused on counselling and education for Hispanic patients with dia-
betes led to reductions in fasting plasma glucose (p = 0.019), SBP (p = 0.003), and triglycerides
(p = 0.003) from baseline to 12 months, but not in mean HbA1c. Subgroup analyses of patients
with poorly controlled diabetes at baseline showed significant reductions in mean HbA1c,
SBP, diastolic blood pressure (DBP), and lipids [71]. A record/chart review in the United States
found that diabetes management led by clinical pharmacists [102] was associated with a reduc-
tion in mean HbA1c and an increase in patients achieving HbA1c <7% over four years. How-
ever, no significant improvements were found in SBP, DBP, lipid measures, or medication
adherence.
Two studies found no impact of pharmacists on outcomes. A randomised controlled trial
in the United States exploring the impact of a pharmacist intervention (including meetings
and phone-calls to initiate care plans) on poorly-controlled patients with diabetes managed in
primary care found no difference in mean HbA1c or self-reported medication adherence [33].
A cohort study in the United States found no significant effect on medication adherence asso-
ciated with the presence of a pharmacist in Veterans Affairs clinics [77].
Nurses: Eight studies, all quantitative, looked at the impact of nurses on diabetes control
and adherence outcomes. All but one [99] took place in high-income countries. Three studies
found positive impacts on control of service delivery by nurses. A Dutch randomised con-
trolled trial explored the impact of transferring routine aspects of diabetes care in hospital out-
patient clinics to diabetes specialist nurses [29]. After one year, significantly more patients
receiving care from nurses achieved HbA1c <7% compared to the control group. A Cameroo-
nian pre-post study [99] found a significant reduction in mean fasting blood glucose (FBG) in
non-insulin-dependent patients’ following a nurse care empowerment scheme. A Danish
cross-sectional study [67] found that the proportion of patients with HbA1c8% significantly
decreased in general practices with well-implemented nurse-led diabetes consultations, com-
pared to practices without.
One record/chart review in the United States reported mixed results. It evaluated the
impact of incorporating nurse practitioners into collaborative practices with primary care cli-
nicians [106] and found that, post-intervention, 50% of patients achieved HbA1c <8% com-
pared to 0% of patients pre-intervention (p<0.001). There were no significant changes in the
proportion of patients achieving BP and cholesterol targets.
Four studies, all trials, reported no significant effects of service delivery by nurses on diabe-
tes control. Two were conducted in the Netherlands and examined the impact of diabetes
management by nurses [27] and nurse-driven, protocol-based correctional therapy on patients
[50]. Two were conducted in the United States and explored the effect of nurse-led behavioural
management [37] and empowerment of nurse practitioners to provide comprehensive patient
care [31].
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Physicians: Six studies, all quantitative and conducted in high-income countries, investi-
gated the impact of physicians on diabetes outcomes. A cohort study in the United States
found that 10% increased frequency of therapeutic intensification (i.e. increasing the dosage or
amount of hypoglycemic medication a patient takes) by a physician was associated with a
0.15% lower level of HbA1c (p<0.0001) among patients in an urban health system. A single
episode of therapeutic intensification was associated with an average 0.7% reduction in HbA1c
(p<0.001) [85].
A record/chart review in the United States reported that newly-diagnosed patients with dia-
betes at a family medicine clinic of a university hospital with a regular physician reported
lower mean HbA1c values than patients without a regular physician [103]. A Dutch record/
chart review found that symptom-catalysed (encouraged by the onset of symptoms in the
patient), opportunistic, or patient-requested general practitoner (GP) screening activity was
significantly related to the presence of a diabetes diagnosis [101].
A review of United States claims records found a positive association between physicians’
certification by a national-level quality assurance organisation and patient adherence [105].
Patients managed by certified physicians were more likely to receive oral anti-hyperglycaemic
drug prescriptions (mean prescriptions per patient per month 0.49 vs. 0.46, p = 0.02).
An Australian cross-sectional study compared the impact of vocationally-registered vs.
non-vocationally-registered general practitioners (GPs) on diabetes control [59]. Vocational
registration entails the enrolment of GPs as part of improving professional standards, reward-
ing high-quality practice, and enabling GPs’ access to higher rebates in the publicly-funded
universal healthcare system. It found no difference in mean HbA1c. A United States cross-sec-
tional study [70] found an association between patient-physician gender concordance and dia-
betes control, with female patients of female physicians most likely to have HbA1c <8%.
However, this was not due to differences in medication adherence.
Community health workers: Three studies focused on the impact of community health
workers (CHWs). Two reported positive impacts on diabetes outcomes. A ixed-methods study
in the United States found that a culturally-relevant diabetes self-management education pro-
gramme led by trained, bilingual CHW to improved mean HbA1c and SBP among uninsured
and underserved Hispanic patients [114]. An Australian trial found that poorly-controlled
indigenous patients managed in primary care and receiving a clinical, management, education,
and social and family support-focused CHW intervention by a trained indigenous CHW resi-
dent in the community had improved mean HbA1c levels compared to controls [41]. Mean-
while, a randomised trial of Hispanic/Latino patients with diabetes in the United States
managed at family health centres found no differences in control and adherence between
patients receiving care delivered by full-time, trained bilingual CHWs who had T2DM/had
experienced it via a family member or friend vs. case management and standard care [24].
Peers: Two trials investigated the impact of peers on diabetes outcomes. Results were mixed.
A randomised controlled trial in the United States of veterans with poor glycaemic control receiv-
ing usual nurse care vs. reciprocal peer support (i.e. an intervention that encouraged patients with
diabetes to receive and provide support to each other) [44] found that peer support significantly
impro17ved mean HbA1c levels while in those receiving nurse-led care mean HbA1c levels
increased. Among patients with baseline HbA1c<8.0%, patients receiving peer support (-0.88%)
demonstrated greater improvement in mean HbA1c (-0.07%) compared to those receiving nurse
care. Meanwhile, an Irish cluster randomised controlled trial compared outcomes of patients
receiving standardised diabetes care vs. a two-year peer-support intervention [45]. At two-year
follow-up, there were no significant differences in HbA1c, SBP, and total cholesterol.
Intellectual resources. No included studies evaluated the relationship between intellectual
resources, such as use of guidelines, and diabetes outcomes.
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Social resources. No included studies evaluated the effects of social resources on diabetes
outcomes.
Health systems financing
21 studies examined the effect of health systems financing on diabetes outcomes. 15 were
quantitative and conducted in high-income countries: 13 in the United States and two in Can-
ada. Six were qualitative, and all but one [111] took place in lower and middle-income coun-
tries. The high-income country study [111] was the only study not reporting cost or financial
difficulty as a barrier to diabetes control, treatment, or adherence. Table 3 summarises the
findings of included studies exploring the associations between healthcare financing and dia-
betes outcomes.
Cost-sharing and outcomes. Five studies in the United States examined the relationship
between cost-sharing (i.e. when patients pay out-of-pocket for a portion of healthcare costs
not covered by health insurance) on outcomes. All studies found that adherence and/or con-
trol measures decreased as cost-sharing increased. These findings were consistent across dif-
ferent types of cost-sharing and health schemes [60, 65, 74, 78, 80].
Insurance status and outcomes. Four studies looked at the impact of insurance status on
outcomes. All were from the United States and cross-sectional. One found that publicly-
insured patients had significantly lower mean HbA1c values (p<0.001) and better control
(HbA1c7%, p<0.001 than those with private insurance [66]. A study of elderly patients
found that privately insured patients were almost twice as likely to report diabetes medication
underuse compared to patients in the Veterans Affairs system (p<0.0001) [56]. Another study
using national data [62] found the highest diabetes control among commercially-insured
patients, compared to those covered by Medicare or Medicaid, but adherence was higher
among Medicare beneficiaries. Another explored the impact of socioeconomic factors on con-
trol among newly-diagnosed patients with diabetes participating in a community-wide screen-
ing programme [53] and found that lack of insurance coverage was predictive of patients
failing to seek medical care.
Extent of healthcare insurance and outcomes. Six studies looked at the impact of differ-
ent levels of healthcare insurance coverage (i.e. the extent to which different care services,
treatment options, medications, and/or self-monitoring and testing equipment are covered
under a healthcare insurance pan) on outcomes. Four found that broader coverage was associ-
ated with better outcomes. Two, a time-series study among patients with a health maintenance
organisation in the United States [107] and a Canadian cross-sectional study of patients receiv-
ing care at community pharmacies [52], found that the provision of free monitors/testing sup-
plies (e.g. blood glucose monitors, insurance coverage for supplies e.g. glucometer strips)
improved control.
Two studies, both from the United States, found that increased coverage of drugs was asso-
ciated with improved adherence. A cohort study examined the relationship between Medicare
Part D benefit coverage (a federal government programme to subsidise the cost of prescription
drugs and drug insurance premiums for Medicare beneficiaries) [75], finding that beneficiaries
without coverage (OR 0.617, P<0.0001, 95% CI 0.523, 0.728) or generic coverage only (OR
0.702, P<0.001,95% CI 0.604, 0.816) were less likely to be adherent than those with full cover-
age of generic and branded drugs. A pre-post study found that uninsured outpatients partici-
pating in a pharmacy-managed medication programme providing free medication [92] had
significant reductions in mean HbA1c (p = 0.002) and total cholesterol (p = 0.001), and an
increase in proportion of patients achieving HbA1c <7%. However, a Canadian randomised
controlled trial of free (versus out of pocket payment) self-monitoring supplies [39], found no
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Table 3. Summary of findings of studies examining the associations between healthcare financing and T2DM outcomes.
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets Where
Available)
Risk of Bias
Assessment
Health Systems Financing
Cost-sharing on outcomes Gibson et al.
2010
USA- patients in a healthcare system
with employer-sponsored benefits
N = 152090
Cross-Sectional • For OAD users, the OR for non-adherence
as prescription drug cost sharing increased
was 0.974 (0.970–0.984, p<0.1); for OAD-
only users, the OR was 0.978 (0.973–0.984,
p<0.01)
• For all OAD users, the OR for non-
adherence with increasing cost-sharing for
physician visits was 0.996 (0.994–0.997
p<0.01); for OAD-only users the OR was
0.995 (0.993–0.996, p<0.01)
Low risk of
bias
Cost-sharing on outcomes Hsu et al. 2006 USA- Medicare+ choice
beneficiaries in a Kaiser permenente
health system
N = 199179
Cohort • For subjects with capped benefits, OR for
non-adherence to antidiabetic drugs was 1.33
(1.18–1.48)
• OR for elevated glycated hemoglobin was
1.23 (1.03–1.46)
Low risk of
bias
Cost-sharing on outcomes Hunt et al. 2009 USA- patients enrolled in a
commercial exclusive provider
organization plan having different
cost-sharing amounts
N = 5189
Cohort • For each $5 increase in cost share, 0.1
increase in HbA1c (p = 0.02)
• For every increase in patient cost share by
$1, 1.2% reduction in odds of oral diabetic
medication adherence (p<0.0001)
Low risk of
bias
Cost-sharing on outcomes Ngo-Metzger
et al. 2012
USA- ethnically diverse patients in
various outpatient clinics
N = 1361
Cross-sectional • Perceived financial burden as associated
with HbA1c 8% (aOR = 1.7, 95%CI 1.09–
2.63)
• Being uninsured (aOR = 1.9, 95%CI 1.13–
3.21) and non-adherence (aOR = 1.49, 95%CI
1.06–2.08) associated with HbA1c
Medium risk
of bias
Cost-sharing on outcomes Elliott et al.
2013
USA- patients in a private health
system
N = 242
Cohort • Between baseline and follow-up, no
significant changes in glycemic control
• Participants were more likely to self-report
being adherent to oral diabetes medications at
1-year follow-up (p = 0.011).
Medium risk
of bias
Insurance status on outcomes Grogan et al.
2010
USA- participants in the bypass
Angioplasty Revascularization
Investigation 2 diabetes trial
N = 776
Cross-Sectional • Compared to patients with private or no
insurance, patients with public insurance
have lower mean A1C (private 8.2 vs. public
7.7 vs uninsured 8.29, p<0.001) and lower
proportion of patients with A1C 7%
(private 71.6% vs. public 61.2% vs. uninsured
68.3%, p = 0.001)
Low risk of
bias
Insurance status on outcomes Piette et al. 2004 USA- Veteran affairs health systems
N = 766
Cross-Sectional • Patients with private insurance almost twice
as likely to report underusing medication in
the prior 12 months as VA patients (P
<0.0001)
• Patients who reported cost-related
medication underuse had an average HbA1c
of 8.7% (p<0.001)
• Cost-related medication underuse
associated with 0.6% (0.2–0.9) absolute
increase in HbA1c levels (p = 0.005)
High risk of
bias
Insurance status on outcomes Tan et al. 2015 USA- Nationwide data
N = 452383
Cross-Sectional • Diabetes control was highest at 68.9% for
commercially insured patients (69.1–68.7)
than 53.7% for Medicare (53.5–54.0) and
52.7% for Medicaid patients (52.3–53.0)
(p<0.05)
• Average PDC and drug adherence were
higher at 83% (82.9–83.1) for patients insured
by Medicare than 76.6% (76.5–76.8) for
patients who were commercially insured and
74.4% for Medicaid insured (74.2–74.6)
(p<0.05)
Medium risk
of bias
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Table 3. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets Where
Available)
Risk of Bias
Assessment
Socioeconomic factors on
healthcare seeking behaviour
of newly diagnosed persons
with T2DM
Burge et al.
2000
USA-community-wide diabetes
screening programme
N = 118
Cross-Sectional • Lack of insurance coverage as primary
reason that patients with newly diagnosed
diabetes fail to seek medical care (p<0.001)
High risk of
bias
Extent of insurance coverage
and outcomes
Soumerai et al.
2004
USA- patients of a health
management organization
N = 3219
Time-series • Initiation of self-monitoring (as a result of
financial coverage) not associated with
improved HbA1c levels in those with good or
adequate baseline glycemic control
• Among those with poor glycemic control,
initiators of self-monitoring lowered their
mean HbA1c level by 0.63% compared with
noninitiators (1.14–0.12, p = 0.03)
• Compared with noninitiators of self-
monitoring, initiators had improvements in
regularity of medication use by 6 months after
initiation: −19.5 days between dispensings
among those with low refill regularity (27.7
−11.3); −9.7 days among those with moderate
regularity (12.3−7.1), and mean HbA1c level
reduced by 0.63% (1.14% -0.12%)
• Among those with moderate refill regularity
by 6 months after initiation of self-
monitoring, initiators reduced mean gaps
between dispensings by 9.7 days compared
with noninitiators (12.3−7.1)
• Among those with low baseline refill
regularity, initiators of self-monitoring had
immediate reductions in mean gaps of 19.5
days compared with noninitiators (27.7−11.3)
Medium risk
of bias
Extent of insurance coverage
and outcomes
Bowker et al.
2004
Canada- patients managed in
pharmacies
N = 405
Cross-Sectional • Patients with insurance had lower HbA1c
than patients without insurance (7.1 vs. 7.4,
p = 0.03)
• Patients with insurance for testing strips had
significantly lower HbA1C concentrations
(adjusted difference 0.5%, p = 0.006) than
patients without insurance
High risk of
bias
Extent of insurance coverage
and outcomes
Johnson et al.
2006
Canada–patients without private
insurance and not using insulin
N = 458
Randomised
Controlled Trial
• Reducing financial barriers by providing
free testing strips did not significantly
improve glycaemic control in patients
Medium risk
of bias
Extent of insurance coverage
and outcomes
Gu et al. 2010 USA- prescription drug claims data
by national pharmacy benefit
management company
N = 12881
Cohort • Patients with no coverage in the Medicare
Part D coverage gap had a 38% reduction
(OR = 0.617, P<0.0001, 95% CI = 0.523,
0.728) in odds of being adherent after
reaching the Medicare Part D coverage gap,
compared with patients with full coverage
• Patients with only generic coverage in the
Medicare Part D coverage gap had a 30%
reduction (OR = 0.702, P<0.001,95%
CI = 0.604, 0.816) in odds of being adherent
after reaching the Medicare Part D coverage
gap, compared with patients with full
coverage
Medium risk
of bias
Extent of insurance coverage
and outcomes
Patel et al. 2006 USA- Patients in an outpatient
medical assistance programme
N = 143
Pre-post • 0.85% reduction in HbA1c (0.34–1.37,
p = 0.002)
• 33% increase in patients who achieved
HbA1c <7% (p = 0.008)
• Total cholesterol decreased by 25.7mg/dl
(11.1–40.2. p = 0.001)
Medium risk
of bias
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difference in six-month HbA1c between intervention and control groups. Only one cohort
study examined the relationship between type of healthcare financing plan and adherence
among Medicaid patients from across the country [82]. It found that patients in capitated
plans had 5% lower mean oral antidiabetic adherence than those in fee-for-service plans
(p<0.05).
Impact of financial factors on outcomes. Six studies, all qualitative, reported on the
impact of financial factors (e.g. cost of services, medication, lifestyle management, and the abil-
ity of persons with diabetes to pay for them) on outcomes. A Tunisian study using interviews
with patients and healthcare professionals in primary care settings [109] and an Indian study
using interviews with patients who have diabetes living in urban slums [110] both found finan-
cial factors to be a key barrier to access to medication, affecting adherence to diet, medication,
blood tests, and referrals. A Bangladeshi study of interviews with patients who have diabetes
managed at various care facilities [108] reported that availability and cost of services impeded
access to appropriate diagnosis and subsequent treatment.
A Kuwaiti study using interviews with patients who have diabetes and are on oral medica-
tion managed in general practice or hospitals [112] reported unavailability of medications, dif-
ficulties accessing physicians and medications, inequalities in care provision and medication
supply at different healthcare facilities, and lack of trust in the government healthcare system
as barriers to adherence. A South African study interviewed low-income female patients with
diabetes [113] and found that patients’ adherence to medication was affected by structural
Table 3. (Continued)
Health System Arrangement Study Setting and Sample Size Study Design Findings (95% CIs Given in Brackets Where
Available)
Risk of Bias
Assessment
Extent of insurance coverage
and outcomes
Pawaskar et al.
2010
USA- state level Medicaid patients
N = 8581
Cohort • Patients in capitated plans had 5% lower
mean oral antidiabetic medication adherence
than those in fee for service plans (p<0.05)
• Odds ratio of adherence among patients in
capitated health plans was 0.89 (0.82–0.98,
p = 0.05) of medication adherence compared
to patients in fee for service plans
Low risk of
bias
Barriers to achieving diabetes
self-management
Gazmararian
et al. 2009
USA- economically disadvantaged
patients with diabetes
N = 35
Qualitative • Cost not mentioned as a barrier to
medication adherence
Low risk of
bias
Barriers to primary care
management
Alberti et al.
2007
Tunisia- Patients with diabetes and
healthcare providers in primary care
N = 26
Qualitative • Patients and health professionals quoted
financial reasons as the cause of poor patient
compliance (compliance in this study refers
to adherence to diet, medications, blood tests
and referrals)
Low risk of
bias
Health system constraints in
managing T2DM
Bhojani et al.
2013
India- Patients with diabetes in an
urban slum
N = 16
Qualitative • Financial constraints as major barrier to
accessing chronic illness medication that
should be taken for years or a lifetime
Low risk of
bias
Patients perspective of care Lewis et al. 2014 Bangledesh- Patients with diabetes
managed in various healthcare
facilities
N = 31
Qualitative • Access to appropriate diagnosis and
subsequent treatment was restricted by
availability and costs of services
Medium risk
of bias
Barriers in medication taking Jeragh-
Alhaddad et al.
2015
Kuwait- Patients with diabetes
managed in GP or hospitals
N = 20
Qualitative • Unavailability of medications, difficulties
accessing physicians and medications,
inequalities in care provision and medication
supply at different healthcare facilities, and
lack of trust in the government healthcare
system as barriers to medication adherence
Low risk of
bias
Experiences of diabetes care Mendenhall
et al. 2015
South Africa- Low income black
patients with diabetes
N = 27
Qualitative • Structural barriers, e.g. overcrowded clinics
and poor access to medicines, as impeding
adherence to treatment
Low risk of
bias
https://doi.org/10.1371/journal.pone.0195086.t003
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factors in the health system, including overcrowded clinics and poor access to medicines.
However, a series of study of focus groups conducted in the United States with economically-
disadvantaged urban-dwelling African-American patients with diabetes [111] found that the
main contributors to lack of medication adherence were denial of consequences and a lack of
understanding of the disease, and not cost or financial concerns.
Service delivery
26 studies investigated the relationship between health service delivery and diabetes outcomes.
Table 4 summarises the findings of studies examining associations between service delivery
and diabetes outcomes.
Innovative/integrated models of care. 14 studies examined the impact of innovative/
integrated care delivery models on outcomes. In this review, we define innovative/integrated
care delivery models as multifaceted care models that bring together different components of
services towards improving outcomes.
Five studies took place in Europe: one each in Spain [84], the Netherlands [73], Denmark
[47], the United Kingdom [79], and Italy [97]. Three studies were set in Asia: two in China
[25, 43] and one in Thailand [86]. Three studies took place in the United States [87, 104, 116],
and one each was in Australia [51], the Middle East [93], and Central America [83].
Despite variation in types of innovation/integration of care employed, implementation
sites, and country settings, 11 studies found positive associations between innovative/inte-
grated models of care delivery on diabetes control and adherence outcomes. A Chinese trial
among older patients with diabetes receiving hospital-based specialist care [25] found
improved mean HbA1c in the group receiving integrated care compared with the traditional
model. An Australian trial [51] found that mean HbA1c at 12 months significantly decreased
in a group receiving integrated community care while there was no significant change in a
control group.
Three cohort studies found improved outcomes. A Dutch study [73] found that mean
HbA1c and the proportion of patients with poor control both fell significantly in a group
receiving structured care (i.e. the implementation and practice of care processes as per clinical
practice guidelines) from general practitioners but rose in the control group during 2 years of
follow-up. Good control (HbA1c <7%) was achieved in 54.3% of those receiving structured
care compared to 44.1% of controls (p = 0.013). A Mexican study of group management found
that mean fasting plasma glucose and BP were significantly lower at 15 months’ follow-up than
in controls receiving usual treatment [83]. A Spanish evaluation of a multifactorial interven-
tion in primary care centres [84] found highly significant improvements in a wide range of
biochemical parameters after one year.
A Thai case-control study [86] found significantly lower mean HbA1c and a significantly
higher proportion of patients with HbA1c<7% in those managed in a community clinic
emphasising promoting continuity of care compared to those receiving standard care in an
outpatient hospital setting. A cross-sectional study in the United Kingdom found that an inte-
grated "care package" [79] was associated with lower HbA1c values and increased probability
of meeting cholesterol (4mmol/l) and BP (140/80mmHg) targets compared with controls
receiving usual treatment.
Three other quantitative studies found positive results: a pre-post study in the United States
assessing the impact of using the Asheville care management model [87], a record/chart review
also in the United States looking at effects of a diabetes management programme in a univer-
sity health system [104], and an Italian pre-post study assessing the impact of a structured edu-
cation-based model at a diabetes clinic [97]. All three found improvements in achievement of
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Table 4. Summary of findings of studies examining the associations between service delivery and T2DM outcomes.
Health system arrangement Study Setting and sample size Study design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Integrated/ innovative models of care
Multifactorial intervention
(nutritional-hygienic measures,
smoking cessation, and intensification
of pharmacologic treatment with
physicians following clinical practice
guidelines
Tranche et al.
2005
Spain- Primary care centres
N = 3466
Cohort • Significant results (p<0.001) for
baseline vs end point % patients
achieving HbA1c target <7.5% (74.9%
vs 90.6%), all BP goals (<130/85: 3.5%
vs 23.3%, <130/80: 1.8% vs 13.6%,
<140/90: 15.2% vs 72.4%), and lipid
goals (LDL <130 and HDL >40mg/dl:
5.9% vs 40.9%, triglycerides <200mg/
dl: 75.2% vs 89.8%)
• Significant results (p<0.001) for all
indicators comparing baseline and
final visit measurements: SBP (149.7 vs
133), DBP (88.6 vs 79.5), total
cholesterol (223.4 vs 202), LDL-C
(142.1 vs 124.1), HDL-C (49.9 vs 52.7),
triglycerides (158.7 vs 139.4), HbA1c
(6.9 vs 6.5)
Low risk of
bias
Structured care at GP supported by
allied health, with computerized
patient register
De Sonnaville
et al. 1997
Netherlands–patients managed in
general practice
N = 359
Cohort • At 2 years, mean HbA1c decreased
from 7.4 to 7.0% in structured care
patients and rose from 7.4 to 7.6% in
usual care patients (p = 0.004)
• % patients with HbA1c >8.5%
decreased from 21.4% to 11.7% in
structured care patients and rose from
23.5% to 27.9% in usual care patients
(p = 0.008)
• HbA1c <7% achieved in 54.3% of
those receiving structured care
compared to 44.1% of usual are
patients (p = 0.013)
Medium risk
of bias
Structured personal care including
quarterly consuiltations and
individualized goal setting for risk
factors
Nielsen et al.
2006
Denmark- Patients in primary care
settings
N = 874
Cluster
randomised
pragmatic trial
• Median HbA1c level was 8.4% in
women receiving structured care vs.
9.2% in women receiving usual care
(p<0.001)
• Women receiving usual care had
HbA1c levels 1.1 times higher than
women receiving structured care
(1.06–1.14, p<0.001).
High risk of
bias
“Care package” for patient including
Motivational interviewing for goal
setting by healthcare professional,
financial incentives based on network
achievement of targets and the
formation of GP networks
Hull et al.
2014
UK- clinical data used in assessing
quality improvement in a primary
care trust
N = 41210
Cohort • Average HbA1c value of all patients
with T2DM fell from 7.80% to 7.66%
between 2009 to 2012
• Achievement of cholesterol and BP
targets increased from 35.3% to 46.1%
Low risk of
bias
Structured education program based
on patient empowerment managed by
multidisciplinary team
Musacchio
et al. 2010
Italy-diabetes clinic
N = 1004
Pre-post • % of patients with HbA1c 7%
increased from 32.7% to 45.8%
(p < 0.0001) after 12 months follow-up
• % of patients with HbA1c 9%
decreased from 10.5% to 4.3%
(p < 0.0001) after 12 months follow-up
• % of patients with LDL-C < 100 mg/
dl increased from 39.7% to 47.3%
(p < 0.0001) after 12 months follow-up
• % of patients with LDL  130 mg/dl
decreased from 26.6% to 19.7%
(p<0.001) after 12 months follow-up
Medium risk
of bias
Integrated health management model
including health record establishment,
health evaluation and health
management
Chao et al.
2015
China- patients receiving care
from an endocrinology clinic in a
district hospital
N = 100
Randomised
controlled trial
• Mean FBG in the management group
-0.82 mmol/l vs. usual care group
+0.06m/mol (p = 0.042)
High risk of
bias
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Table 4. (Continued)
Health system arrangement Study Setting and sample size Study design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Case management of patients with
diabetes in outpatient settings
Yuan et al.
2016
China- Hospital
N = 120
Randomised
controlled trial
• HbA1c reduced in CM group
compared to control group at 6
months compared to baseline, with
least mean of 0.43 (95% CI: 0.83, 0.03,
p = 0.034)
• Statistically significant reductions
did not persist at 12 and 24 months
• % of participants with HbA1c7.0%
was higher over time in the CM group
(45.5% at baseline, 54.5% at 6 months,
60.0% at 12 months, and 61.8% at 24
months)
• At 24 months, % of participants with
HbA1c 7.0% higher in CM group than
in control group (61.8% vs. 41.5%,
P = 0.035)
Medium risk
of bias
Continuity of care clinic by general
internal medicine specialists
Chalermsri
et al. 2014
Thailand–patients managed at
continuity of care clinic
N = 757
Case-control • Mean HbA1c lower in Continuity of
care (CC) clinic group vs. Outpatient
department (OPD) group (7.3 vs. 7.8,
p<0.001)
• No. of patients who achieved HbA1c
<7% in CC clinic group was 123
(32.1%) vs. 91 (24.3%) in the OPD
group (p = 0.039)
Medium risk
of bias
Establishing patient education goals,
hiring diabetes nurse care managers
and developing clinical practice
guidelines to managing risk factors,
delivering appropriate
pharmacological therapies, conducting
regular laboratory evaluations and
specialist referral
Maschak-
Carey et al.
1999
USA- patients recently in the
emergency department or had
been admitted to the hospital for
diabetes-related problem
N = 1779
Record/
chart review
• Before enrolment, average HbA1c
values were 9.03 and fell in study
participants to 8.3 (p = 0.03).
Medium risk
of bias
Care management model including a
medical record system, training
providers and rectifying care gaps
Bunting et al.
2011
USA- self-insured health plan
members
N = 149
Pre-post • % patients achieving HbA1c goals
increased from 38% to 53%
• % patients achieving LDL-C goal
increased from 46% to 67%
• % patients achieving BP goals
increased from 55% to 72% (SBP and
60% to 71% (DBP)
• No p-values were reported
High risk of
bias
Telephone based non-professional
patient navigation for patients who
were knowledgeable of the community
resources
Loskutova
et al. 2016
USA- patients managed in primary
care
N = 179
Mixed methods • Compared with baseline, reduction
in HbA1c after the intervention (7.8 vs
7.2%, p = 0.001) among subgroup of
patients with an existing diagnosis of
T2DM
High risk of
bias
Management of patients through
integrated primary/specialist model of
community care (multidisciplinary
clnic screening, development of
patients’ specific management plan)
Russell et al.
2013
Australia- primary care in a
population with high proportion
of ethnic or indigenous population
N = 328
Trial • Mean HbA1c in intervention group
decreased from 70.4 mmol/mol to 60.7
mmol/mol at 12 months (mean
difference -9.0; 95% CI -12.2 to -6.4,
p<0.05)
• After stratification into quartiles
based on baseline HbA1c, the
intervention group had lower HbA1c
after 6 months
• % participants in intervention group
achieving HbA1c target of 53 mmol/
mol (7%) increased from 21 to 42%
(P<0.001); no significant increase in
usual care group
Medium risk
of bias
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Table 4. (Continued)
Health system arrangement Study Setting and sample size Study design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Structured diabetes care (protocol
based care, patient education program)
Reed et al.
2001
UAE- primary care centres
N = 219
Pre-post • No statistically significant differences
in baseline and post-intervention for
mean fasting blood glucose (FBG),
mean DBP change, mean SBP change,
and total cholesterol
Medium risk
of bias
Primary care group visit model of care
(patient activation, patients receiving
support in group setting)
Salinas-
Martinez et al.
2009
Mexico- healthcare facility which
implemented cooperative health
care clinic
N = 1201
Cohort • At 15 months’ follow-up, mean FPG
lower in group visit patients compared
to usual care patients (155.3 ± 59.5 vs.
175.7 ± 67.7 mg/dL, p0.01)
• SBP and DBP lower in patients on
group visits (SBP 123.6 ± 13.4 vs. 127.5
±12.8 mmHg, p <0.01 and DBP
73.5 ± 8.5 and 79.4 ± 6.3 mmHg, p
<0.01)
Low risk of
bias
Coaching and education
Patient participation programme
which included two 2-hr teaching
sessions about ways to achieve control
of modifiable risk factors
Rachmani
et al. 2005
Israel–patients referred to a
diabetes clinic of an academic
hospital
N = 141
Randomised
controlled trial
• Between baseline and 4-year follow-
up, patient participation group had
greater reductions in HbA1c (9.6 vs.
8.9), SBP (160 vs. 148), DBP (95 vs.
88), and LDL-C (148 vs. 124)
compared to standard care group
(p<0.05 for between-group
differences)
• Between baseline and 8-year follow-
up, patient participation group had
greater reductions in HbA1c (9.6 vs.
9.2), SBP (160 vs. 147), DBP (95 vs.
85), and LDL-C (148 vs. 128)
compared to standard care group
(p<0.05 for between-group
differences)
High risk of
bias
Administration of education and
health behaviour classes, delivered by
nurse and dietitian, in a primary care
setting
Ridgeway
et al. 1999
USA–general internal medicine
patients receiving care in an
ambulatory clinic
N = 56
Randomised
controlled trial
• After 6 months, intervention group
had reductions in mean FBG (from
215 to 180mg/dl, p = 0.024), mean
glycated hemoglobin (12.28% to
10.21%, p = 0.034), mean LDL-C (133
to 113 mg/dl, p = 0.313), and mean
total cholesterol (59 to 221 mg/dl,
p = 0.0129)
•
High risk of
bias
Longer patient-physician interaction,
health education forums and patients
discuss their experiences of
management
Mshelia et al.
2007
Nigeria- Patients in a metabolic
research unit or medial outpatient
department
N = 220
Trial • Reduction in % patients with good
fasting glycaemic control in the
intervention group vs. control group
(52.1% vs 48.8%, p<0.05)
• Difference in % of patients who had
food 2HPP glycaemic control in
intervention group vs. control group
(47.9% vs 35.4%, p<0.05)
High risk of
bias
Outpatient diabetes education
programme delivered by certified
diabetes educators (who are either
registered nurses or dietitians)
Kiblinger
et al. 2007
USA- patients referred by
physicians to attend outpatient
diabetes programme
N = 501
Pre-post • Pre-post mean HbA1c decreased
from 7.9% to 6.7% (p = 0.001)
• Among patients with uncontrolled
diabetes (HbA1c >7.0%), decrease in
mean HbA1c between baseline and
follow-up (9.1% vs. 7.1%, p<0.001)
• Medication adherence increased
from 5% to 21% for four classes of
medication: antihypertensive agents,
aspirin, injectable insulin, and insulin
sensitizers (p = 0.001).
Medium risk
of bias
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Table 4. (Continued)
Health system arrangement Study Setting and sample size Study design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Diabetes service which provides
counselling and monitoring for
patients with type 2 diabetes
Groeneveld
et al. 2001
Netherlands- patients in general
practice
N = 246
Randomised
controlled trial
• Among those with poor initial FBG
(FBG >10mmol/l), mean HbA1c of
intervention group patients was lower
than that among control group
patients (p = 0.001).
Medium risk
of bias
Structured group education program
delivered in community by healthcare
professionals
Davies et al.
2008
UK- patients managed in primary
care
N = 824
Randomised
controlled trial
• No significant mean change in
HbA1c from baseline to 12 months
• Reduction in triglyceride levels at 8
months: Intervention -0.57mmol/l
(-0.71–-0.42), control -0.34 mmol/l
(-0.53–-0.15), p = 0.008
Medium risk
of bias
Motivational interviewing and health
coaching over the phone
Browning
et al. 2016
China- patients in government run
community health stations
N = 668
Cluster
randomised
pragmatic trial
• No differential treatment effect for
HbA1c, with treatment and control
(i.e. usual care) groups both showing
improvement
Low risk of
bias
Individually tailored education by
visiting nurses, assessing patients
educational background and level of
understanding alongside family and
environmental factors
Ko et al. 2011 South Korea–low-income patients
with diabetes in a public health
centre
N = 96
Pre-post • Significant relationship between the
provision of individually tailored
education programmes for diabetes
management and FBG levels (chisq
40.11, p = 0.005)
Medium risk
of bias
Adherence information provided to
physician; motivational interviewing
delivered by trained staff
Pladevall et al.
2015
USA- patients in a health system
N = 1692
Randomised
controlled trial
• No significant differences between
groups’ HbA1c and LDL-C levels at 18
months post-randomisation compared
to usual care
• No significant differences between
groups at other time points post-
randomisation (6 months, 12 months)
for HbA1c, LDL-C, oral diabetes
medication adherence, lipid lowering
medication adherence
Medium risk
of bias
Healthcare type/setting
Differences in treatment between
public health centre and private clinic
Panarotto
et al. 2009
Brazil- patients managed in public
health service or private clinic
N = 357
Cohort • Patients in public health centre had
worse HbA1c (baseline 9.7 vs. final 8.3)
data than patients in private clinic
(baseline 8.3 vs. final 7.5) (baseline vs.
final p<0.05, between-group difference
p<0.01)
• Patients in public health centre had
worse cholesterol (baseline 205.1 vs.
final 188.7) outcomes than patients in
private clinic (baseline vs. final 205.8
vs. final 172.1) (baseline vs. final
p<0.05, between-group difference
p<0.01)
• Frequency of visits was a
determinant of better control (B = 0.72
95%CI: 0.55,-0.93, p<0.01)
Low risk of
bias
Status of diabetes control comparing
primary healthcare setting vs.
secondary/tertiary healthcare setting
Tai et al. 2006 Taiwan- Primary and secondary/
tertiary healthcare facilities
N = 1302
Cross-Sectional • Primary care patients had worse
HbA1c data than secondary/tertiary
care patients (primary care 8.4 ± 1.8%
vs. secondary/tertiary care 8.1 ± 1.6%,
p < 0.001)
• Primary care patients had better BP
control than secondary/tertiary care
patients (BP target 140/90 mmHg,
primary care 42.3% vs. secondary/
tertiary 46.6%, p < 0.05)
Medium risk
of bias
Access and Use •
(Continued)
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control outcomes (e.g. proportion of patients achieving HbA1c, SBP, DBP, and cholesterol
goals). A mixed-methods study in the United States evaluated a ‘Patient Navigator Model’
[116], finding lower mean HbA1c post-intervention (7.8% vs 7.2%, p = 0.01).
Two trials obtained mixed results. A Chinese trial of a case management, behaviour
change-focused, protocol-driven model of care in an outpatient hospital setting [43], found
that mean HbA1c was significantly reduced in the case management group at six months. A
Danish trial of a structured personal care model [47] found a significant benefit only among
female patients: the median HbA1c level was 8.4% in women receiving structured care vs.
9.2% in women receiving usual care. A pre-post study in the United Arab Emirates found no
effect of an integrated care model on outcomes in primary care facilities [93].
Coaching and education. Nine studies, all quantitative, focused on the impact of deliver-
ing services including coaching and education. Four found positive effects on control and
adherence.
An Israeli trial compared the impact of standard care with a participative programme
including education and lifestyle modification among patients with diabetes, hypertension,
and hyperlipidaemia [28]. Over a mean follow-up of 7.7 years, mean HbA1c, SBP, DBP and
LDL-C values were significantly lower in the intervention group. A US trial found that nurse
and dietitian-administered diabetes education and health behaviour classes delivered in pri-
mary care were associated with significant reductions in mean FBG, mean HbA1c, mean
LDL-C, and mean total cholesterol [34]. A Nigerian trial examining the impact of prolonging
physician-patient interaction and incorporating health education forums for patients with dia-
betes found a significant difference in the percentage of patients who had good fasting glycae-
mic control and 2-hour post-prandial glycaemic control in the intervention compared to the
control group [49].
Table 4. (Continued)
Health system arrangement Study Setting and sample size Study design Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Access (i.e. insurance status, perceived
trouble accessing care, perceived access
to medication, and usual place of care)
to healthcare on glycemic control
Rhee et al.
2005
USA- outpatient diabetes
programme catered to a largely
41-African-american population
with limited financial resources
and at high risk of complications
N = 605
Cross-Sectional • Health insurance was not
significantly associated with HbA1c
Average HbA1c levels were higher in
people who reported trouble accessing
medical care (9.4%, p<0.001) and in
those with no prior need for care (10%,
p<0.001), compared to those with no
trouble getting care (8.7%)
• Compared to those reporting no
trouble getting medications (8.9%),
those with no prior need for
medications had higher HbA1c (10%,
p<0.001)
• Compared to those with doctor’s
office as usual place of care (8.6%),
those seeking care at an acute facility
9.5%, p<0.001) and nowhere 10.3%,
p<0.001) had higher HbA1c
• Having trouble getting care was
associated with a 0.57% increase in
HbA1c (p = 0.04), use of an acute care
facility was associated with 0.49%
higher HbA1c (p = 0.047) and having
gone nowhere for care was associated
with 1.08% higher HbA1c compared to
going to a doctor’s office
High risk of
bias
https://doi.org/10.1371/journal.pone.0195086.t004
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A pre-post study in the United States found that an outpatient diabetes education pro-
gramme delivered by certified diabetes educators, who are either registered nurses or dieti-
tians, was associated with decreased mean HbA1c (p = 0.001) and increased medication
adherence for antihypertensive agents, aspirin, injectable insulin, and insulin sensitisers
(p = 0.001). Among patients with uncontrolled diabetes (HbA1c >7.0%), there was a signifi-
cant decrease in mean HbA1c between baseline and follow-up [90].
Two studies obtained mixed results. A randomised controlled trial conducted in the Neth-
erlands found that providing counselling to patients managed in general practice had no sig-
nificant effect on mean HbA1c after a year [38]. However, among those with FBG>10mmol/l,
the mean HbA1c of intervention group patients was lower than that among control group
patients (p = 0.001). A British randomised controlled trial examining the impact of a health-
care professional-delivered structured group education programme delivered in the commu-
nity found no statistically significant differences in mean HbA1c of the structured group
education arm compared to the control group [36]. However, the intervention group showed a
reduction in triglyceride levels at eight months (intervention -0.57mmol/l (-0.71–-0.42) vs.
control -0.34 mmol/l (-0.53–-0.15), p = 0.008).
Three studies–a Chinese randomised pragmatic trial of telephone-based motivational inter-
viewing (MI) and health coaching [48], a South Korean pre-post study of individually-tailored
diabetes education by visiting nurses on low-income patients [96], and an American rando-
mised controlled trial of provision of adherence advice and/or MI [40] found no significant
impact of coaching and education-based interventions on control and adherence.
Healthcare type/setting. Two studies, both quantitative, looked at the impact of health-
care type/setting on diabetes outcomes. A Brazilian cohort study compared those attending a
public and private clinic [81]. While both groups showed improvements across all clinical
parameters, patients receiving public healthcare had significantly higher mean HbA1c and
mean cholesterol than private care patients. A Taiwanese cross-sectional study explored differ-
ences in control outcomes among patients receiving care in primary vs. secondary/tertiary
healthcare settings [61] and found that patients in primary care had higher mean HbA1c val-
ues but better BP control than patients in secondary/tertiary care.
Access and use. A cross-sectional study in the United States examined the impact of
access to healthcare on diabetes control among patients receiving care from a large two-county
public health system delivering services to a vulnerable, high-risk minority ethnic group popu-
lation. This study looked at different facets of access including the availability of insurance cov-
erage, experience of seeking care, and the ability to access medication. Having trouble getting
care was associated with a 0.57% increase in HbA1c (p = 0.04), use of an acute care facility was
associated with 0.49% higher HbA1c (p = 0.047) and having gone nowhere for care was associ-
ated with 1.08% higher HbA1c compared to going to a doctor’s office. Lack of insurance was
not found to be associated with levels of HbA1c [57].
Governance
Two included studies evaluated the effects of health system factors relating to governance chal-
lenges. Table 5 summarises the findings of studies examining associations between governance
and diabetes outcomes.
Two cross-sectional quantitative studies looked at the impact of patient-physician relation-
ships on diabetes outcomes. Both studies found that the nature of patients’ relationships with
physicians impacted control and/or adherence. A Danish study found that patients whom GPs
classified as not knowing well had relatively higher mean HbA1c and fasting plasma glucose
levels compared to those of patients classified as known “well” or “fairly well” [64]. A study in
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th United States found that among patients reporting high levels of physician trust, rates of
cost-related medication underuse significantly increased from 4% among patients with low
monthly out-of-pocket costs (<US$51) to 11% among patients with high monthly out-of-
pocket costs (>US$100) [55].
Complex interventions: Studies with more than one building block
Seven studies evaluated outcomes incorporating components from multiple health systems
domains. Three took place in high-income countries [54, 72, 95], five were quantitative [54,
63, 69, 72, 95], and one was mixed-methods [115]. Three studies looked at the combined
impact of more than two health systems components. Table 6 summarises the findings of stud-
ies examining associations between complex interventions and diabetes outcomes.
A South African mixed-methods study looked at the impact of service delivery, intellectual
inputs, and governance, examining the effect of a programme combining the Chronic Care
Model with primary care nurse support, medication scale-up, and improved access to specialist
care [115]. It reported improved disease awareness through early detection and detecting
patients with advanced disease, and improved treatment through referral of high-risk, poorly
controlled patients. A German prospective survey found that systems-level changes, including
specialist physicians, structured teaching and training programmes, postgraduate training
courses for physicians and staff, and increased access to self-monitoring equipment were asso-
ciated with improvement in mean HbA1c and percentage of patients with mean HbA1c
<7.2% between 1989 to 2000 [72]. A Mexican cross-sectional study assessing the impacts of
healthcare financing and physical and human resource inputs [58] found that uninsured
patients were more likely to have mean HbA1c >12.0% than insured patients, that municipali-
ties with more health units in relation to population had more patients with poor HbA1c (OR:
3.17), and insured patients and those living in areas with more nurses per 1,000 population
had a greater likelihood of not having poor HbA1c (OR: 4.59).
Remaining studies looked at the combined impact of two health systems components. Two
cross-sectional studies, one each from the United States [54] and the Philippines [69], looked
at the combined impact of service delivery and intellectual inputs, with a focus on the con-
cepts/principles of the Chronic Care Model. Both studies found positive relationships between
service delivery founded in the Chronic Care Model and diabetes control (e.g. mean HbA1c)
and awareness (e.g. odds of being tested for HbA1c, FBG, lipids) outcomes.
Table 5. Summary of findings of studies examining the associations between governance and T2DM outcomes.
Health system arrangement Study Setting and sample size Study
design
Findings (95% CIs Given in Brackets Where Available) Risk of Bias
Assessment
Governance
Patient-doctor relationship and
diagnosis of T2DM in patients
Drivsholm
et al. 2006
Denmark- newly
diagnosed patients
managed in general
practice
N = 1136
Cross-
sectional
• Patients classified as not knowing their GPs well had
relatively high HbA1c levels compared with levels
among other patients (known well 10.2% vs. known
fairly well 10.2% vs. not known well 11.3%, p<0.0001)
• Patients classified as not knowing their GPs well had
relatively high FBG compared with other patients
(known well 13.7mmol/l vs. known fairly well 13.6
mmol/l vs. not known well 14,8mmol/l, p = 0.007)
Low risk of bias
Trust in physicians and its
moderating effect on cost-
related nonadherence
Piette et al.
2005
USA- Veteran Affairs
health system
N = 912
Cross-
sectional
• Among patients with high levels of physician trust,
rates of cost-related underuse increased (p = 0.001) 4%
among patients with low monthly out-of-pocket costs
(<$51) and 11% among patients with high monthly
costs (>$100)
• Rates of underuse increased from 4% to 30% (p = 0.01)
among patients with low levels of physician trust.
High risk of
bias
https://doi.org/10.1371/journal.pone.0195086.t005
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Table 6. Summary of findings of studies examining the associations between studies with more than one health systems building block and T2DM outcomes.
Health system arrangement Study Setting and sample size Study
design
Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Complex interventions
Studying health system change over time
(reimplementation of specialist
physicians for diabetes care, structured
teaching and training programmes,
postgraduate training courses for
physicians and staff for treatment and
performance of structured teaching and
training programmes)
Schiel et al.
2006
Germany- Insulin treated
T2DM patients
N = 323
Cohort • Relative HbA1c improved over time
(1989/90 = 9.17, 1994/5 = 9.01, 1999/
2000 = 7.57: p<0.05 for 89/90 to 99/00,
and 94/95 to 99/00)
• % of patients with relative HbA1c
<7.2% improved over time 89/
90 = 23.7%, 94/5 = 18.8%, 99/00 = 3.5%:
p<0.05 for 89/90 to 99/00, and 94/95 to
99/00)
Medium risk of bias
Primary care clinics’ service delivery
consistency with the Chronic Care Model
using ACIC scores as a measure
Parchman
et al. 2007
USA- Primary care clinics in
a research network
N = 618
Cross-
Sectional
• The total Assessment of Chronic
illness Care (ACIC) score inversely
associated with HbA1C control after
controlling for patient demographics
and self-care behaviors, with HbA1C
0.073 points lower for each 1-point
increase in ACIC score (p<0.001)
• This relationship was strongest among
patients who had not adhered to
exercise in the past 6 months (A1C
0.1404% lower, p<0.001)
High risk of bias
Impact of enrollment in public health
insurance on blood glucose control in
poor adult diabetics
Sosa-Rubi
et al. 2009
Mexico- adults with diabetes
in a national survey
N = 1491
Cross-
Sectional
• Uninsured patients had very poor
HbA1c control (>12.0%) in greater
proportion than insured patients (46.2%
versus 36.7%, p<0.01)
• Municipalities with more health units
per 1000 population had a greater
likelihood of being the place of
residence of those with poor HbA1c
(OR: 3.17; z-statistic: 2.08)
• Insured patients and people living in
areas with more nurses per 1000
population had a greater likelihood of
not having poor HbA1c (OR: 4.59; z-
statistic: 1.75)
High risk of bias
Performance-based provider
compensation program in a
disadvantaged population
Coleman
et al. 2007
USA- patients in an
underserved population
N = 1166
Pre-post • Implementation of the pay for
performance programme program
increased the probability of receiving 2
HbA1c tests by 15.67%(p<0.0001)
compared to not having the pay for
performance program
Medium risk of bias
Decentralization of diabetes services at
the primary health care and community
levels using a participatory local
development approach
Pilleron
et al. 2014
Philippines- 14 Barangays
(small administrative
division; village or ward)
N = 1457
Cross-
sectional
• Mean HbA1c were 7.8% (SD: 1.9) and
8.5% (SD: 2.0), 62 and 69 mmol/ mol,
respectively in the intervention and the
control groups (p = 0.003)
• % patients achieving HbA1c <6.5%
(48 mmol/mol) was higher in the
intervention group compared to the
control group (p = 0.013)
Low risk of bias
Different public health facility types on
diabetes care (hospital with specialist
(HS), hospital without specialist(HNS),
health clinics with family physicians(CS)
and health clinic without doctor (CND)
Chew et al.
2013
Malaysia- patients managed
in different public health
facilities
N = 57780
Cross-
sectional
• Compared to HS (reference category),
a higher proportion of CS patients
achieved HbA1c6.5% (OR = 1.20, 95%
CI = 1.06–1.37)
• Compared to HS, a higher proportion
of CS patients achieved BP <130/80
(OR = 1.36, 95%CI = 1.17–1.57)
Low risk of bias
(Continued)
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A Malaysian cross-sectional study examining the impacts of service delivery and human
resource inputs on diabetes control [63] found that patients at a hospital with specialists had
significantly lower mean HbA1c, LDL-C, and higher mean HDL-C than patients at a health
clinic with family physicians, a health clinic without a doctor, and a hospital without special-
ists. Patients at a health clinic with family physician were most likely to achieve HbA1c 6.5%
(aOR 1.2) and BP targets (aOR 1.4). Patients at a hospital without specialists were 3.4 times
more likely to not achieve LDL-C targets. A pre-post study in the United States examining the
impacts of service delivery and healthcare financing on outcomes [95] found a performance-
based provider compensation programme significantly increased the probability of disadvan-
taged, underserved patients receiving two HbA1c tests by 15.67%.
Health systems complexity considerations
67 of the 93 studies did not address interdependence and linkages between health system
domains [25–30, 33–40, 42–46, 48–52, 56, 59, 61, 62, 65–68, 72–78, 80–87, 89–95, 97, 98, 103–
107, 115, 116]. Of the studies which did, three considered linkages between human inputs and
service delivery [69, 88, 99]. These studies considered the need for sufficiently trained health-
care professionals beyond simply delivery of healthcare services on outcomes.
Five studies considered interdependencies between healthcare financing and service deliv-
ery [32, 55, 100, 102, 114]. They pointed to high costs of associated services required for diabe-
tes care and control, particularly with regard to the cost of prescription medication. One study
pointed to a lack of understanding among clinicians, arguing that “physicians’ role in influenc-
ing patients’ response to medication costs [are] not well understood” [55].
Four studies considered the linkages between multiple, dynamic health system domains
[108–110, 112]. These tended to study health system barriers and facilitators of diabetes care
using qualitative methodologies. For example, a Tunisian study invited patients and healthcare
professionals to discuss the barriers they faced in receiving and providing care. The findings
were positioned in relation to several health system domains, namely inputs (i.e. human, phys-
ical, intellectual resources), service delivery, and healthcare financing [109].
14 studies considered the interactions of other factors not usually covered within the health
system building blocks, but still linked to the health system. Five considered patients’ socioeco-
nomic status [53, 57, 64, 101, 111], of which two discussed issues facing low-income patients
[58, 96]. Five studies considered ethnic factors [24, 41, 60, 71, 113]. Two studies considered the
Table 6. (Continued)
Health system arrangement Study Setting and sample size Study
design
Findings (95% CIs Given in Brackets
Where Available)
Risk of Bias
Assessment
Role of Primary Healthcare nurses
provided decision support, escalated
scaling up of medication, and prompt
access to specialist care
Katz et al.
2009
South Africa- primary care
nurses and patients in a
programme modelled after
the chronic care model
N = 257
Mixed
methods
• Programme successful in supporting
Primary Health Care Nurses (PHCN)s,
detecting patients with advanced
disease, and ensuring early referral to a
specialist center
• Programme improved early detection
and referral of high risk, poorly
controlled patients and had an impact
on PHCNs’ knowledge
• Disadvantages: poor follow up due to
poor existing health systems and
inability to integrate into existing
chronic disease services
• No clinical outcomes were reported
Quantitative section
High risk of bias,
qualitative section low
risk of bias
https://doi.org/10.1371/journal.pone.0195086.t006
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role of gender [47, 70]. These studies explored how patients’ demographic characteristics
might interact with different health system domains and affect outcomes.
Discussion
This systematic review sought to assess the influence of health systems-level factors on T2DM
awareness, treatment, adherence, and control. Despite the limited scope and variable quality of
included articles, we identified several key health system facilitators and barriers to diabetes
control, treatment, adherence, and awareness outcomes. Several studies also reported on
health system factors which were neither facilitators nor barriers, showing no statistically sig-
nificant impact on outcomes.
We confirmed the importance of two important health system barriers to effective diabetes
care. The first was the presence of financial constraints faced by the patient. These were either
self-reported or implied by the presence of co-payments for medication and were found to be
a barrier to control and/or adherence outcomes. We also showed that reducing out-of-pocket
payments could improve diabetes outcomes. Second, lack of access to health services and med-
ication was a barrier to achieving good diabetes outcomes, with the evidence primarily from
qualitative studies.
We also found three health system facilitators. First, integrated, innovative care models
were positively associated with improved diabetes outcomes. These results are consistent with
studies of integrated care programmes for other chronic diseases [117, 118]. Despite the het-
erogeneity of integrated care models and the national settings where they were implemented,
many studies that yielded positive results had certain commonalities, namely patient educa-
tion/empowerment, care continuity, data management, task-sharing, and multidisciplinary/
team-based care. Yet it remains unclear what is the right mix of integrated care components
and whether some are more important than others. Also, as most of these studies were in high-
income countries, their applicability to low- and middle-income settings is unclear. It is also
important to note the lack of consensus on definitions of “innovative” and “integrated care”
[119, 120] and the components/elements that constitute an “integrated” care model [121, 122]
in the health systems research community. Second, there is evidence to support pharmacist
involvement. While this is consistent with findings in other chronic disease outcomes, as well
as several meta-analyses [123, 124], we cannot rule out the potential of publication or reporting
bias informing our findings. In this review, we surprisingly found fewer papers on nursing
that we did pharmacists. This may be because nursing models are better established and there-
fore less novel, with fewer publications relevant to the aims of this review–but not necessarily
less effective or impactful than pharmacist care models. Third, education programmes led by
health professionals showed mostly positive effects on control.
Several other health systems facilitators were identified, namely peer support, positive
patient-physician relationships, and multi-faceted interventions, but there is rather less evi-
dence to draw on.
Study strengths and limitations
This review has several strengths. It includes a wide range of measures of control, treatment,
awareness, and adherence. Its conceptual framework, building on previous work by Maimaris et al
[20] and Balabanova et al [13], enabled studies to be linked to different health systems domains.
Our systems approach helps us map the global landscape of health systems-related research on dia-
betes outcomes, identifying geographical and topic gaps in research and variation in types and rig-
our of studies conducted, thereby informing decisions on needs for future research.
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Another strength is the inclusive view of governance that encompasses the relationships
and everyday practices of actors in the health system. By regarding governance as practices
that are driven by macro- or meso-level decision-making, but operationalised by individuals at
lower levels in the health system [125], this review harkens to the move to make health systems
research a “people-centred science”, as “it is people who ultimately determine the character of
a health system” in their capacities as users, providers, managers, knowledge agents, and finan-
cers [126]. It also recognises the importance of complexity in health systems research [17, 18].
This is consistent with recent calls in the health systems research literature to recognise that
health systems are influenced by the settings in which they operate [126], and that health needs
and outcomes are dynamic, evolving, and generated and shaped by social, economic, political,
historical, and cultural forces [127].
Additionally, we did not apply language restrictions to our systematic review, which
allowed us to search for, retrieve, and consider studies that were not published in English,
thereby reducing language-related publication bias. We conducted searches of smaller, more
regionally-focused databases (e.g. WPRIM), increasing our likelihood of capturing regional or
smaller-scale research that may not have been accessible via or indexed in larger, standard aca-
demic databases.
This study is not without limitations. Heterogeneity of study designs, populations, analyti-
cal strategies, and effect measures meant it was not possible to conduct a meta-analysis.
Included quantitative studies were of variable methodological quality, as evinced by the large
proportion of studies rated as having an overall high risk of bias and and correspondingly
small number of studies assessed to have low risk of bias across methodological domains.
Although most included qualitative studies were found to have low risk of bias, it was not pos-
sible to draw causal inferences from them. As such, inferences about temporal and/or causal
relationships between systems-level factors and diabetes outcomes could only be made for a
limited number of factors, with careful consideration of context.
We are unable to exclude publication bias or reporting bias. For example, studies exploring
effects of various factors on diabetes outcomes may have neglected to report results for health
systems domains which did not achieve statistical significance. Furthermore, the review found
that work from the United States was overrepresented, which provides helpful insights into
gaps in the literature, but limits the applicability of our results to other contexts. Additionally,
we found that limited evidence of studies assessing awareness as an outcome. Most awareness
studies found in the initial search were focused on relationships between demographic and
social factors (e.g. sex, age, educational level, income) on awareness, and not relationships
between systems-level factors and awareness. Also, due to our focus on health systems factors
and awareness, control, treatment, and adherence outcomes, it was not within this review’s
scope to address broader questions around the sustainability (e.g. cost-effectiveness, cost-bene-
fit) of interventions and programmes targeted at improving diabetes outcomes.
Policy implications
This review found an association between minimising out-of-pocket payments (e.g. drugs,
self-monitoring equipment) and improved control and adherence in the North American con-
text. This highlights the importance of reducing, or ideally eliminating, out of pocket costs of
both prescription medication and monitoring supplies. It is unfortunate that few such studies
were conducted elsewhere. There seems to be potential for moving to integrated care models
where these do not yet exist, taking into account synergies between the dynamic and interact-
ing components of integrated care models, including healthcare professionals aspects of care
(e.g. education, empowerment, social support, case management), approaches to care delivery
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(e.g. structured care, multidisciplinary team care), and information technology (e.g. clinical
decision support systems, shared electronic medical records).
Previous evidence has shown that task-sharing with non-physician healthcare workers
improves management of non-communicable diseases [128]. Consistent with this, our review
found evidence of an association between outcomes and sharing of certain care services and
processes with pharmacists. However, it is not possible to rule out the influence of publication/
reporting bias, and evidence remains dominated by studies from the United States.
Research implications
This study points to several possibilities for future research. Although we found evidence to
support integrated, innovative care models, their implementation must be underpinned by a
robust evidence base. As such, more studies looking at the impact of different types of care
integration models on diabetes outcomes should be conducted. These studies may also gener-
ate valuable insights on which “mix” of care components and what types of integration are
most conducive to achievement of positive outcomes.
There is also a need for more high-quality, longitudinal studies identifying the effect of
health system arrangements on a variety of different outcomes. Studies of screening tended to
be focused on uptake and adherence and not health and social outcomes. Additionally, we
found diverse measures of medication adherence. There is a clear need for greater consistency
here. Importantly, there were few studies focusing on upstream health system factors such as
leadership and governance affecting good diabetes outcomes. For example, achieving inte-
grated and innovated care delivery models is often dependent on effective management and
lateral team management including different specialities, while expanding financial protection
among larger sections of the population often results from political will; more research is
needed on these associations.
Lastly, most studies are in high income countries. As the global prevalence of diabetes
rises [129–131] and the influence of health systems factors on chronic disease control and
management is increasingly recognised [132–134], efforts to generate evidence from low
and middle-income countries (LMICs), especially considering their diverse population charac-
teristics, diet and lifestyle shifts, sociocultural contexts, and health systems, should be
augmented.
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